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Abstract 
 
Inflammation is defensive host response that occurs from infection and injury and the 
inflammatory process is the pivotal physiological response of our body and essential part of the 
human physiology. Due to the mechanistic relationship between chronic diseases and inflammation, a 
better understanding for the molecular mechanism of chronic inflammation could attenuate cellular 
inflammation pathways. Under inflammatory pathways, the impetus of proinflammatory mediators 
usually caused by the increased expression of transcriptional factors which is also a potential targets 
in the development of novel and effective anti-inflammatory therapeutics. Among others, we are 
interested in the Nuclear Factor Kappa-B (NF-κB) which is reported as a major mediator that 
regulates inflammatory gene expression and also decrease the prevalence of inflammation responses. 
To suppress the inflammatory activity, inhibitors that could selectively target this protein are needed. 
We therefore, chose the natural product cerulenin which has been studied widely because of its 
antifungal and antibacterial properties, for designing inhibitors. In light of the interesting inhibitory 
properties displayed by cerulenin for fatty acid synthase (FASN), we were keen to explore the 
possible binding mode of this natural product with a view to design various derivatives that would be 
amicable to synthetic manipulation in order to enable SAR studies. Potent analogues of cerulenin, 
with various chain lengths and substitutions, are synthesized and evaluated for their ability to inhibit 
NF-κB enhanceosome. Taken together, by identifying target protein with constructed inhibitors 
derived from cerulenin might give revolutionary effect on discovering new therapeutic agents. 
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I. INTRODUCTION 
Inflammation is defensive host response that occurs from infection and injury which are caused 
by foreign substances such as bacteria and viruses. Inflammation process is the pivotal physiological 
response of our body and essential part of the human physiology. However, inflammatory pathways 
dysregulation can lead to either acute or chronic inflammatory diseases. Acute inflammation is first 
defensive attempt of our body against injury and infectious agents. If it fails to remove exogenous 
stimuli or the symptoms lasts more than few weeks, it can become chronic and may serve as a genesis 
of various diseases. Contrast to acute inflammation, chronic inflammation which pathomechanism is 
less understood, persist over several months or years and eventually leading to other chronic diseases 
as well as cancer. Continued inflammation acts as major drivers for the development of inflammatory 
diseases like asthma, rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD), 
inflammatory bowel disease (IBD), multiple sclerosis (MS), and psoriasis. Moreover, inflammatory 
responses play roles in the progression of several permanent diseases including cancer, atherosclerosis, 
diabetes, obesity, and Alzheimer; and this ardent phenomenon provide clues to understand different 
inflammatory markers. In chronic inflammation, inflammatory cells respond to external 
proinflammatory factors and inflammatory stimulus like environmental pollutants, viruses, bacteria, 
food, stress, etc; and generate bioactive mediators such as transcription factors (NF-kB, STAT) and 
their gene products such as cytokines (IL-1, IL-6, TNF-α), chemokines (IL-8, VCAM-1), chemokine 
receptors and COX-2. Despite the essentiality of these molecules in normal cell regulation processes, 
uncontrolled and too high expression to those molecules can result in chronic disorders.1 As these 
mediators have complex, pleiotropic effects, it interacts with many cell types to amplify the 
inflammatory response. Therefore, due to the mechanistic relationship between chronic diseases and 
inflammation, a better understanding for the molecular mechanism of chronic inflammation could 
attenuate cellular inflammation pathways. 
 
Figure 1. External/internal proinflammatory factors and their biological responses 
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1.1. DISEASES ASSOCIATED WITH CHRONIC INFLAMMATION 
To fully understand the relationship between inflammation and the diseases, we need to know 
some major diseases that associate with chronic inflammation. Moreover, pathogenesis of these 
chronic inflammatory diseases will forest new therapeutic approaches for anti-inflammatory remedy. 
There are various immune-mediated inflammatory diseases but we will focus on the most common 
ones which are rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD) and 
inflammatory bowel disease (IBDs). It is not mentioned in this paper, but other autoimmune diseases 
like multiple sclerosis (MS) and psoriasis also have their own distinct pathogenesis. 
1.1.1. Rheumatoid arthritis (RA)  
Arthritis is the typical type of disease that takes huge part in inflammatory diseases. Among 100 
different forms of arthritis, Rheumatoid arthritis (RA) is a chronic systemic disorder which affects 
about 1% of the worldwide population, most commonly middle-aged women. Though the exact cause 
for RA is not yet wholly established, it is characterized by cytokine mediated chronic inflammation of 
the synovium inside of the joints that leads to destruction of cartilage and bone.2 From the process of a 
massive infiltration of leukocytes into the synovial tissue leads to production of proinflammatory 
mediator, cytokines. Cytokines which maintain the inflammation and degrade proteoglycans and 
collagen, eventually result in tissue breakdowns and destroy the nearby articular cartilage.3 The 
proximate triggers of synovitis in the affected joints still a matter of debate, but activation of toll-like 
receptor (TLR) on T cell is implicated.4 It is well established that interleukin-1 (IL-1), and interleukin-
6 (IL-6) and tumor necrosis factor α (TNFα) are pivotal cytokines that starts the proinflammatory 
cascade in RA.5 Currently, the treatment for RA consist of glucocorticoids and NSAIDs, but only a 
small portion of ongoing clinical trials for treating RA are conducted with small molecules having 
anti-inflammatory properties. 
1.1.2. Chronic obstructive pulmonary disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease 
which associated with an abnormal response in the lung and also with systemic inflammation caused 
by inhalation of noxious gas and particles. Statistic data from the World Health Organization (WHO) 
shows 65 million people suffer from COPD, and more than 3 million people died from it in 2005 and 
it is considered as a significant health burden worldwide. Now, COPD is the fourth leading cause of 
death in the world, but will rise to third by 2030. The pathomechanism of COPD involve with the 
increased systemic oxidative stress and activation of inflammatory cells from severe inflammatory 
process in the airways.6 Initiators of this abnormalities are not clearly identified but neutrophils and 
macrophages are thought to be responsible for the release of proteases, cytokines (IL-1, IL-8, TNF-α, 
and LTB4) and mediators, which lead to inflammation and remodeling.7 Therefore, from this pathway, 
patients with COPD suffers from chronic airflow limitation, chronic bronchitis and emphysema 
accompanied by mucus hypersecretion.8 unfortunately, there is no cure for COPD and the available 
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medications that is in the market is unable to stop the deterioration in lung function. Since drugs that 
are mostly used for COPD only treat symptoms and have no progress on stopping inflammatory 
process, there is a large unmet need for drugs. 
1.1.3. Inflammatory bowel disease (IBD) 
Inflammatory bowel disease (IBD), generally characterized to two major forms, ulcerative colitis 
(UC) and crohn's disease (CD). IBD is a chronic intestinal inflammatory disease caused by 
dysregulated immune response which occurs from increased activity of the immune system in the 
intestinal microflora, then leads to tissue damage. Etiologies of these processes remain uncertain but 
both genetic and environmental factors are responsible for intestinal inflammation. Cytokines 
associated with IBD are IL-6, IL-1B and TNF-α which stimulate the production of CRP.9 So far, there 
is no efficacious pharmacological treatment for both UC and CD. Currently, diverse strategies that 
have anti-inflammatory properties for treating IBD are in clinical development. Besides biological, 
only about 16% of recent clinical trials to manage IBD have been performed with small molecules.10 
  
1.2. VARIABLE SMALL MOLECULES TO TARGET INFLAMMATORY MEDIATORS 
Currently, many new pharmacological approaches to map the pathology of immune-related 
inflammatory diseases are ventured to minimize the inflammation. Anti-inflammatory drugs can be 
classified by their chemical properties into biologicals and small molecules, which can be subdivided 
to steroidal and non-steroidal agents. Though the biologicals cause huge influence in the autoimmune 
disorder and cancer market, a strong need for small molecules that are safe and potent is demanded. 
Practically, small molecules are much economical compared to biologics and can easily be taken 
orally. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most prevalent drugs for the treating 
inflammation, while glucocorticoids considered as strongest weapons among others against acute 
phases of chronic inflammation. Sadly, both type of treatment for various inflammatory diseases are 
not satisfying. Therefore, it is important to focus on small molecules in clinical trials for chronic 
inflammatory diseases that particularly belong to the field of immune-mediated inflammatory diseases 
(IMIDs). 
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Figure 2. Category of anti-inflammatory drugs and outline of the drug classes 
 
A wide spectrum of drugs and natural compounds has been established to be useful reducing 
agent for inflammation process, it is important to know about the root causes and their mechanism of 
inhibition. There are some drugs that are developed for one particular disease, but in most cases for 
new inflammatory targets are involved in broad spectrum of diseases. From these aspects, it is 
important for us to know better about the current clinical anti-inflammatory approaches for the targets. 
Approaches are distributed by their mode of action into four classes and various agents in clinical 
trials are also demonstrated together.  
 
1. Agents inhibiting the effect of mediators on the extracellular side; Chemokine receptor, 
Arachidonic acid metabolites, ligands of adenosine, ligand-gated ion channel 7 (P2X7), oxidized 
phospholipids (OxPL), very late antigen-4 (VLA-4), S1P, chemoattractant homologous receptor 
expressed on Th2 cells (CRTh2), α7-nicotinic acetylcholine receptor (nAChR) 
1.1. Chemokine receptor antagonists 
Chemokine receptors take huge part in regulating the immune system, and therefore regarded as 
prospective targets for treating various inflammatory diseases. Chemokine receptors are sorted by 
several types. CCR1 antagonist AZD4818 which is inhalable was registered in phase II for COPD. It 
showed safety and efficacy but failed to give a clinical profit.11 Another CCR1 antagonist CCX354 
showed adequate safety and efficiency in randomized, placebo-controlled phase IIa with RA 
patients,12 and further phase IIb is ongoing. CCR2 antagonist AZD2423 has gone through phase I and 
II specifically for the treatment of pain which showed little clinical efficacy but rather satisfying 
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safety and tolerability.13 Interestingly, CCR5 is the only chemokine receptor that is implemented in a 
marketed drug which is CCR5 antagonists Maraviroc.14 CCR9 antagonists vercirnon exhibits efficacy 
on crohn's disease in phase II with well tolerance and safety, but failed to meet desirable end points in 
phase III where it didn’t show greater improvement.15 CXCR2 antagonists danirixin has gone four 
phase I studies for inflammatory diseases and showed good pharmacokinetics profile in COPD. 
Recently, therefore a phase II clinical trial has been investigated to observe clinical benefit of oral 
danirixin in COPD patients. Navarixin subjected to seven clinical trials and at phase II for asthma 
didn’t give significant improvement than phase I with healthy volunteers. Other CXCR2 antagonists 
AZD5069 showed safety and tolerability in a phase I and also was tested in a phase II trial for COPD 
and asthma. 
1.2 Arachidonic acid cascade 
The arachidonic acid (AA) cascade can be targeted either with NSAIDs directly or indirectly 
with glucocorticoids. Arachidonic acid (AA) metabolites, prostaglandins and leukotrienes are well 
known for significant role as proinflammatory mediators.16 The 5-lipoxygenase (5-LO) is an 
important enzyme for metabolism of AA to leukotrienes. So far, zileuton is only one to be addressed 
to the market as direct 5-LO inhibitor to treat asthma, but no significance in RA nor IBD.17 Another 5-
LO inhibitor setileuton was evaluated in a phase II clinical trial for COPD, but it didn’t show more 
effectiveness than placebo. 5-lipoxygenase-activating protein (FLAP) inhibitor fiboflapon showed 
satisfactory clinical results in preclinical and phase I clinical trial.18 The LTB4 receptor antagonist 
amelubant (BIIL284) is evaluated in phase II clinical trials for COPD and phase I for RA which result 
is rather disappointing.19 
1.3 Adenosine receptor ligands 
Selective A3AR agonist CF101 (CanFite BioPharma's) showed a good clinical benefit on 
symptoms and biomarkers of RA and also for plaque psoriasis in phase II.20 A phase III trial for 
psoriasis with CF101 is ongoing. 
1.4 Oxidized phospholipids  
VB-201 recently entered in phase II clinical trials for active plaque psoriasis. VB- 201 is a small 
synthetic molecule which belongs to the class of the lecinoxoids, but has no proinflammatory activity. 
1.5 Integrin receptor antagonists  
In phase II clinical trial, firategrast significantly reduced new lesion formation in proportion to 
placebo at high dosage. Moreover, firategrast displayed acceptable safety and tolerability, but could 
observe little adverse event.21 
1.6 S1P receptor ligands  
Fingolimod is a molecule that targets S1P signaling which has become a vital target for treating 
especially for MS, has recently approved in the market to treat MS. The S1PR1 and S1PR5 selective 
agonist siponimod and the S1PR1 agonist ponesimod are dominating the clinical network showing 
11 
significant clinical benefit in phase II trials. 22 Two other promising S1P agonists, ceralifimod and 
GSK2018682 are also in MS pipline.23 
 
 
 
12 
O N
HO OH
N
H
O
N
N
N
HN
I
CF101
Adenosine receptor ligands Oxidized phospholipid
O
O
C
16
H
33
HO
O
O
P OO
O
N
VB-201
S1P receptor ligands
F
3
C
O
N
N
O
OH
OHO
Cl
S
N
O
NOH
O
O
N
O
OH
N
O
O
N
N
N
O
HO
Siponimod
Ponesimod Ceralifimod
GSK2018682
Integrin receptor antagonists
F
F O
H
N
OH
O
O
O
O
Firategrast (SB683699)
OH
OH
H
2
N
Fingolimod
 
Figure 3. Agents inhibiting the effect of mediators on the extracellular side 
 
2. Agents inhibiting the production of intracellular mediators by interfering with intracellular 
signaling pathways; p38, mitogen-activated protein kinase kinase 1(MEK1), MEKK1, JAK, 
SYK, S1P lyase, DHODH, or PDE ligands 
2.1. Kinase inhibitors 
Kinase inhibitors considered as attractive targets for anti-inflammatory small molecules. 
Especially, p38 MAPK was the first kinase targeting anti-inflammatory drug since it plays pivotal role 
in regulating production of cytokine.24 Several p38 MAPK inhibitors which are talmapimod, 
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pamapimod, and VX-702 entered phase II clinical trials, but failed because of high toxicity and low 
efficacy. MEK-162, the dual MEK1/2 inhibitor exhibited good preclinical results in models of RA, 
and displayed well tolerance in a phase II clinical trial but did not give contentable result.25 As dual 
MEK1/MEKK1 inhibitor E6201 showed good result in several preclinical for psoriasis26, entered two 
phase II for psoriasis but no results have been published so far. Two tyrosine kinases, JAK and SYK 
are targeted for inhibiting pathogenesis of RA. The selective JAK3 inhibitor decernotinib (VX-509) 
showed clear efficacy in a phase IIa trial for RA and also undergoing phase II b study.27 Recently, 
JAK3/JAK1 inhibitor tofacitinib (Xeljanz®) a highly potent molecule was approved by the FDA for 
diverse severity of RA treatment. The dual JAK1/2 inhibitor baricitinib showed improvement in a 
phase II trial for signs and symptoms of RA28 and undergoing four phase III trials. SYK inhibitor, 
fostamatinib (Astra Zeneca’s) revealed significant efficacy and achieved desired end points in most 
cases at phase II trials for RA.29 
2.2. S1P Lyase inhibitor 
From the fact that S1P signaling can be regulated with S1P lyase (SPL), it got attention. The SPL 
inhibitor LX3305 (LX2931) showed fine safety profile, but did not give satisfying result in a phase IIa 
study for RA. Currently, another phase II trial with higher dosage is ongoing.30 
2.3. DHODH inhibitors 
The first inhibitor of DHODH, teriflunomide (Aubagio®) has recently been approved by the 
FDA, for treatment of MS. Another DHODH inhibitor vidofludimus (ENTRANCE) revealed 
significant efficacy for IBD31 and entered two more phase IIa trials which also showed good clinical 
efficiency with CD or UC. From this result, we can expect reduced steroid treatment at the end of the 
trials.32 
2.4. Phosphodiesterase inhibitors 
PDE4 inhibitors roflumilast is the first inhibitor that is approved for efficacy for COPD.33 
Moreover, PDE4 inhibitors came to be interested in other inflammatory diseases like IBD and 
psoriasis. The PDE4 inhibitor tetomilast (OPC-6535) showed rather moderate result in phase I and II 
and recently entered in phase III trial for IBD.34 The inhibitor AN2728 which not only inhibit PDE4 
but also downgrade activation of cytokine undergone clinical trials in phase II for psoriasis and 
entered phase III in sequence  
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Figure 4. Agents inhibiting the production of intracellular mediators by interfering with intracellular 
signaling pathways 
 
3. Agents inhibiting the production of mediators in the cell nucleus by interfering with the 
transcription process; selective glucocorticoid receptor agonists (SEGRA), PPAR, signal 
transducers and activators of transcription (STAT) ligands, IκB kinase 2 (IKK2) modulators, or 
NRF2. 
3.1. SEGRA 
Glucocorticoids (GCs) are most powerful tool for treating acute inflammation with their 
pleiotropic property. However, it is not suitable for chronic inflammation due to side effects. Both 
ZK216348 and a natural product compound A (CpdA) display anti-inflammatory activity in chronic 
diseases. Recently, AZD5423 was evaluated safety and efficacy in phase II for COPD. 
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3.2. PPARγ agonists 
PPARγ participate in inflammation in numerous ways and consider as good drug target. PPARγ 
agonists troglitazone showed good result for psoriasis the in vitro trial. Another PPARγ agonist 
Pioglitazone also showed robust improvement in clinical trial for the psoriasis without adverse 
events.35 In addition, not only the result for clinical trials for psoriasis but also RA and MS is very 
promising.36 
3.3. STAT3 inhibitor 
The STAT3 inhibitor STA-21 showed robust efficacy in trial for psoriasis37 and potentiality for 
RA treatment.38 In addition, possibility of STAT3 inhibitor for treatment for IBD is also mentioned.39 
3.4. IKK-2 inhibitor 
IKK-2 is subunit of IκB kinase and plays potent role in NF-κB pathway which is important for 
regulation of chronic inflammation. The IKK-2 inhibitor IMD-1041 is currently evaluated in a phase 
II clinical trial for COPD, but no results have been confirmed yet and the structure is not disclosed. 
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Figure 5. Agents inhibiting the production of mediators in the cell nucleus by interfering with the 
transcription process 
 
4. Agents directly blocking the cytotoxic effects of enzymes/proteases; Matrix metalloproteinase 
(MMP), Neutrophil elastase (NE), or Cathepsin S inhibitors 
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4.1. MMP inhibitors 
Among several MMPs, MMP-9 was shown to be potential target for MS and COPD treatment.40 
The selective MMP-9 and MMP-12 inhibitor AZD1236, displayed good safety profile but rather 
unsatisfying result in clinical trials for COPD. However, still hold possibility for therapy of COPD in 
a longer trial.41 The dual MMP-13/TACE (TNFα-converting enzyme) inhibitor apratastat undergone 
clinical trial in phase II for RA, but was terminated due to a lack of efficacy. 
4.2. NE inhibitor 
NE inhibitor AZD9668 didn’t show any benefits or effects in phase II clinical trial for COPD.42 
Therefore, it is not certain whether NE could serve as a potential target for a disease relieving agent in 
COPD. 
4.3. Cathepsin S inhibitor 
Cathepsin S serve as attractive target for treatment of autoimmune disease like COPD and 
arthritis.43 Cathepsin S inhibitor RWJ 445380 entered in phase II trials for RA and psoriasis, but no 
results are known so far and the structure is not yet disclosed.  
 
Figure 6. Agents directly blocking the cytotoxic effects of enzymes/proteases 
 
As a demand for better design for inflammation trials and clinical parameters is imperative, 
tracking current clinical breakthrough for inflammatory diseases is important. So far, clinical trials for 
inflammatory, immune-mediated disorders which are RA, MS, IBD, and COPD, take minor part of 
clinical studies of small molecules. Chemokine receptors, the adenosine receptors, p38 MAPKs, JAK, 
PPARγ, STAT3, NRF2, and, MMPs are markedly presented by current research on each target. P2X7, 
S1P, JAK, STAT3 and NRF2 have got spotlighted during the last few years, while a decreasing 
attention can be observed for VLA-4, OxPLs, PDE4 and NE. In this milieu, various new therapeutic 
approaches to interfere with the inflammatory process are under investigation. New molecular targets 
that interfere in the inflammatory process are also being recognized and further studies needs to be 
establish and demonstrate the effectiveness.  
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1.3. A PROMISING THERAPEUTIC TARGET: NF-κB 
Under inflammatory pathways, the impetus of proinflammatory mediators usually caused by the 
increased expression of transcriptional factors that is also a potential targets in the development of 
novel and effective anti-inflammatory therapeutics. The detection of transcription factors is pivotal in 
molecular foundation of chronic inflammatory disease in which the Nuclear Factor Kappa-B (NF-κB) 
is reported as a major mediator that regulates inflammatory gene expression and also decreases the 
prevalence of inflammation responses.44 Therefore, understanding the pathway of controlling 
inflammatory gene expression by the key transcriptional regulator, NF-κB is very important. NF-κB is 
a diametric transcription factor belonging to Rel family with a highly conserved Rel homology 
domain which is responsible for DNA-binding, dimerization and interaction with the inhibitory κB 
protein (IκB).45 Under physiological conditions, NF-κB dimers bind to IκB protein and remain 
inactive in the cytoplasm. Stimulation by inflammatory stimuli such as physical and chemical stresses, 
Bacteria and viruses, ROS, Microbial products (LPS, peptidoglycan) and inflammatory cytokines (IL-
1, TNFα) activate IκB kinases (IKK) that consists of three subunits, IKK-α (IKK1), IKK-β(IKK2) and 
IKK-γ (IKK3 or NEMO). This cascade leads to IκB phosphorylation which then ubiquitinated and 
degraded by proteasome and release NF-κB.46 Once NF-κB (p50 and p65 heterodimer) becomes 
liberated, it is not sequestered to the cytoplasm anymore but translocates into the nucleus and 
activates the transcription of proinflammatory genes and cell adhesion molecules.47 As a result, NF-
κB causes enhanced production of the transcriptional genes that leads inducible expression of the 
mediators like cytokines, chemokines, nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) 
which are indispensable element in inflammatory process. Clearly, targeting the activation of NF-κB 
shows promising avenue for suppressing inflammation and will shed a bright light on designing safe 
and effective drugs that are clinically useful for curing inflammatory diseases.48 
At present, NF-κB and its signaling is one of the most exciting and extensively studied research 
fields since NF-κB dysregulation is associated with numerous chronic diseases including autoimmune 
disorders such as Rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and more permanent 
diseases like cancer, AIDS and diabetes. Several natural and synthetic compounds, including some 
drugs, have been tested for their potential to inhibit NF-κB, but very few of them are suitable for anti-
inflammatory and anticancer therapy. Therefore, it has been suggested that the development of novel 
NF-κB inhibitors with antitumor and anti-inflammatory activities is most demanded.  
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Figure 7. NF-κB activation pathway. 
 
1.4. INHIBITION OF NF-κB SIGNALING 
Current research is venturing to map the different pathways in an attempt to minimize the 
inflammation in chronic diseases by means of various drugs. An extensive collection of drugs that 
inhibit NF-κB are receiving a great deal of attention as an optimal therapeutics for treating 
inflammatory diseases. Drugs targeted against NF-κB complexes can be classified according to their 
action in NF-κB molecular signal transduction pathways and these inhibitors take a wide variety form 
of chemicals, synthetic compounds, metabolites, peptides, natural products, and proteins. To 
understand better about the molecular cascade of NF-κB inhibition, it is important to know the various 
stages of regulation for signaling pathway.49 Generally, regulating NF-κB activation undergoes unique 
multi step procedure including whether it is blocked by incoming stimuli at an early stage of NF-κB 
induction; interfered at cytoplasmic stage by blockage of specific component; or blocked at later 
levels in the NF-κB nuclear activity. Likewise, inhibitors of NF-κB will be classified by which step of 
NF-κB activation is blocked according to mechanism.  
1. Upstream target inhibitors 
As IKK complex plays a prime role in NF-κB activation pathway, the action that block incoming 
signals before it activate IKK would make it possible to inhibit activation of NF-κB. From the fact 
that cytokines, oxidants and other foreign stimuli activate NF-κB by signaling cell-surface receptors, 
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it is clear that anti-TNF agents can limit NF-κB activation and consider as promising candidate for 
anti-inflammatory drugs. Rofecoxib is COX-2 selective inhibitor that blocks NF-κB activation in 
LPS-stimulated macrophage cells.50 Similarly, Ibuprofen inhibit COX-2 expression in T cells and 
another inhibitor, tepoxalin blocks NF-κB activation by suppressing both 5-lipoxygenase and COX. 
Antioxidants are also potential therapeutic inhibitors of NF-κB.51 However, the precise mechanism for 
antioxidants to block NF-κB activation is not known. Despite of the uncertainty, various antioxidant 
molecules are investigated. Both N-acetylcysteine and dithiocarbamates down regulate LPS-mediated 
activation towards NF-κB activity.52 Especially, pyrrolidine dithiocarbamate is a potent molecule that 
inhibited the expression of ICAM-I on IL-1-stimulated fibroblasts which also showed relief of 
symptoms in  experimental with rats.53 Thus, vitamin C and E derivatives, and glutathione 
peroxidase also has inhibitory aspects NF-κB activation by inflammatory stimuli.  
 
Figure 8. Upstream target inhibitors 
 
2. IKK complex activity Inhibitors  
IKK is a pivotal target for the development of NF-κB signaling inhibitors and also for kinase 
inhibitors for therapeutic applications because it takes significant part in NF-κB activation. Over years, 
diverse agents have been discovered which subdue activation at IKK step, but it is still mystery rather 
the inhibitors suppress IKK itself or its activation. A number of nonsteroidal anti-inflammatory drugs 
(NSAID) such as sodium salicylate, aspirin and sulindac inhibit the activity of IKK. Both sodium 
salycilate and aspirin directly bind and inhibit the ATP binding site of IKK-β.54 However, to achieve 
satisfactory NF-κB inhibition, it requires relatively high concentrations because of low specificity. 
Similar to asprin, sulindac which is related to indomethacin structurally and pharmacologically, also 
reduces IKK-β kinase activity and consequently inhibits NF-κB activation.55 In addition, some of 
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natural products also inhibit NF-κB activation in vitro by blocking the activity of IKK. polyphenols 
from green tea inhibit LPS-mediated activation of NF-κB which was confirmed by mice.56 Resveratrol 
which is found in red wine and anti-inflammatory sesquiterpene lactone, parthenolide that is derived 
from medicinal plants, target IKK and also undergo blockage of IκB phosphorylation in specific cell 
types to inhibit NF-κB activity.57 Moreover, Curcumin and capsaicin which can be easily found in 
natural ingredient serve as potent inhibitors of IKK activity in several cell types.58 
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Figure 9. IKK complex activity Inhibitors 
 
3. IκB degradation inhibitors 
3.1. IκBα upregulator 
Some molecules inhibit NF-κB by inducing IκB expression in high level. Glucocorticoids (GC) 
are the molecules that are applicable in this level inhibiting NF-κB with various methods.59 
Dexamethasone increases the level of IκBα, causing NF-κB (p50,p65) to sustain in the cytoplasm.60 In 
addition, hydrocortisone induces the expression of IκBα and inhibit the translocation of NF-κB into 
the nucleus in human cell.61 
3.2. IκB degradation inhibitors 
NSAIDs, sulfasalazine and leflunomide block nuclear translocation of NF-κB through inhibition 
of IκB-α degradation which might have been caused by a direct effect on IKK or upstream signals. 
Sulfasalazine suppresses nuclear translocation of NF-κB by phosphorylation and degradation of 
IκBα.62 Similarly, natural product, gliotoxin from Aspergillus impede the phosphorylation and 
degradation of IκB-α that inhibit activation of NF-κB induced by LPS.63 
3.3. Proteasome/Protease inhibitors 
Activation of NF-κB is possible by proteasome mediated IκBα degradation which is induced by 
phosphorylation after IKK complex.64 Inhibitors that block proteasome activity include several types: 
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peptide aldehydes, lactacystin and its precursor and peptide boronic acids. Two Peptide aldehydes 
MG132 and PSI are potent proteasome inhibitors. MG132 inhibit the chymotrypsin specified activity 
of the proteasome complex that blocks IκBα degradation and prevents radiation-induced activation of 
NF-κB.65 Lactacystin is a very specific targeting inhibitor of the proteasome that reduce proteasome 
activity by acylating threonin residue in the active site.66 Additionally, dipeptidyl boronate analogs 
also serve as proteasome activity inhibitor. Among several molecules, PS-341 and PS-519 are 
showing good efficacy in clinical evaluation. Especially, PS-341 which now called bortezomib is 
approved in U.S. to treat relapsed multiple myeloma and mantle cell lymphoma.67 Moreover, well 
known immunosuppressive agents, cyclosporin A and FK-506 target activation of NF-κB.68 Serine 
protease inhibitors, TLCK, TPCK and DCIC block proteases activity by suppressing IKB 
phosphorylation and degradation. 69 However, these serine proteases inhibitors inhibit NF-κB in all 
cases, but still serve as potent candidate for potent anti-inflammatory drugs.  
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Figure 10. IκB phosphorylation/degradation inhibitors 
 
4. NF-κB nuclear functions Inhibitors 
Last step of NF-κB activation pathway include nuclear translocation, DNA binding and 
transcriptional activation and by blocking these steps, we can successfully inhibit NF-κB activation. 
Inhibitors that block nuclear translocalization are cell pervading peptides which effectively inhibit 
LPS- or TNFα- activated cells. SN-50 and D-amino acid cell-penetrating peptide are the commonly 
used kinds for treatment for inflammatory diseases.70 Attenuating NF-κB DNA binding is possible by 
several sesquiterpene lactones like pathenolide. It not only inhibits DNA binding but also targets IKK 
activity.71 Moreover, κB site decoy oligonucleotides plays crucial role in inhibiting NF-κB DNA 
binding.72 It showed good efficacy in several clinical trials with animals having inflammation and 
cancer.73 The last step in NF-κB pathway that can be blocked is transactivation of specific target 
genes. Natural product maealamine, wortmannin derived from fungi and LY294, 002 blocks specific 
genes induced transactivation of NF-κB.74 Furthermore, particular proteins which are Bcl-2 and 
antithrombin are reported to inhibit transactivation by interfering interactions with RelA.75 
 
 
Figure 11. NF-κB nuclear functions inhibitors 
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Now it is clear that in chronic inflammatory disease, NF-κB takes critical part in regulating genes 
that induce inflammation and also suggests a promising molecular target for the production of 
effective and safe anti-inflammatory drugs. Although various NSAIDs, GCs and others have proven 
to be the potent suppresser for inflammation from intense studies for NF-κB, there are still strong 
eager to find molecules that can directly inhibit specific signaling pathway or molecular target of NF-
κB. In addition, to eliminate unwanted side effects, complete blockade need to be done, so more 
efforts are needed by adjusting the mechanisms that we know so far about inhibitory actions of NF-κB. 
Consequently, careful consideration should be given to inhibitors of NF-κB when developing anti-
inflammatory pharmaceuticals. 
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1.5. TonEBP, POTENTIAL TARGET FOR INFLAMMATION 
Recently, possibilities for new pathogenesis of preventing inflammation is suggested from the 
accumulation of well known transcriptional factor NF-κB and specific protein, Tonicity-responsive 
enhancer binding protein (TonEBP). TonEBP has been identified to be a Rel-like transcription factor 
and designated as a member of the nuclear factor of activated T-cell (NFAT) family NFAT5.76 
TonEBP contains a RHD similar to that in NFAT5 proteins but lacks the translocation domain. 
TonEBP is known to be largely dedicated to regulating osmotic responses induced by hypertonic 
stress in invertebrates and mammals.77 It protects cells from stresses that comes from high 
hypertonicity and acts as important role on cell growth and survival of various organs. TonEBP is 
known to translocate into the nucleus and induce osmoprotective gene, COX-2 enzymes in renal 
epithelial cells in response to hypertonicity.78 TonEBP not only expressed in the kidney but also in 
various tissues, including heart, thymus and brain.77, 79 Among others, TonEBP take huge part in tonity 
regulation in brain, similar to those for the kidney. Therefore, TonEBP in neurological diseases have 
been actively studied.80 It is believe that TonEBP haploinsufficiency decreased NF-κB-mediated 
transcriptional activity and attenuated the severity of neuro inflammation.81 
In addition to well documented classical action of TonEBP in osmoadaptation, recent studies also 
entail tonicity-independent functions of TonEBP might affect a wide range of pathological process 
like inflammation, tumor metastasis, and hepatic detoxification tonicity.82 TonEBP was shown to 
enhance binding of NF-κB by interacting with p65 which is one of the NF-κB subunit and 
successfully induce binding of NF-κB–TonEBP complexes.83 After NF-κB anchors to promoter’s 
target genes and drags TonEBP to protein-protein interaction, NF-κB’s activation increased. 
Therefore, activation rate of TonEBP proportionally determines the activation of NF-κB. As TonEBP 
was found to be the important modulator of NF-κB, the fact that TonEBP takes part in inflammation 
has come up in the surface. Especially, regulating increased expression or activation of TonEBP has 
alleviated inflammatory responses of chronic human diseases including diabetic nephropathy, 
atherosclerosis and rheumatoid arthritis.84 These results enlightens that TonEBP plays a curial role in 
regulating inflammatory signaling in chronic inflammatory diseases and thus give huge impact on 
drug market.  
 
Figure 12. NF-κB enhanceosome complex 
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1.6. CERULENIN, ALSO REMARKABLE INHIBITOR FOR INFLAMMATION 
There have been numerous approaches to find appropriate inhibitor for Fatty acid synthase 
(FASN) which is consider being suitable target for cancer treatment. FASN is a key metabolic 
enzyme involved in catalyzing the terminal steps in long chain saturated fatty acid synthesis.85 
Common in many types of human cancers, overexpression of FASN can be detected and by blocking 
FASN made it possible to induce apoptosis in the cancer cell, eventually inhibits growth of the cancer 
cells.86 One of the most studied inhibitors of FASN is cerulenin, which has been isolated from a 
natural product of Cephalosporium caerulens.87 The natural product cerulenin has been studied 
widely because of its antifungal and antibacterial properties and known to inhibit fatty acid synthases 
(FAS I/ FAS II) and also polyketide synthases which show efficacy against Candida infections.88 
Among two type of FAS which is differentiated by the fatty acid biosynthesis pathway, bacterial fatty 
acid synthase (type II FAS) has gained a lot of interest for a targeting antibiotic therapy including 
anti-cancer and anti-inflammation. So far, antibiotics, which successfully used in clinical use in vivo 
and vitro inhibiting FAS I pathway are triclosan, the anti-Mycobacterium tuberculosis agent and 
isoniazid.89 A further pathway, several inhibitors of FASN have been elucidated and among them, 
cerulenin is believed to act primarily in inhibiting steps at the FAS II pathway though the inhibition of 
that is unselective in FAS I and FAS II system.90 The pathway of FASN is well established in E. coli 
serves as a model to understand type II FAS systems in other bacteria and plants.91 The β-ketoacyl-
ACP synthases is a key component in type II systems by becoming covalently bound to the cysteine 
within the active site and carries the fatty acid intermediates from enzyme to enzyme through the 
cytosol. In addition, cerulenin consider as attractive drug that can defeat Malaria and tuberculosis, 
which are infectious disease.92 Therefore, from this aspect, cerulenin could also give clues for the 
treatment against inflammatory disease.  
 As the mechanism of cerulenin with FASN inhibition in inflammation is not fully understood, 
strong need for the solution is demanded. The structure of cerulenin is composed of an α-keto-
epoxycarboxamide with an octadienyl side chain. It exists in equilibrium between the open chain and 
a cyclized hydroxylactam form (figure 11).93 The epoxycarboxamide moiety has been proposed as the 
“warhead” of the compound, which alkylates the active center cysteine residues in fatty acid synthase 
and palmitoyl acyltransferases, leading to irreversible inhibition. In a number of biochemical studies 
have demonstrated cerulenin analogues in a form of racemic and the homochiral.94 The compound 
which have the 1,4-diene side chain and the cis-epoxy amide function was mainly featured. 
Furthermore, it is shown that the cis-epoxide flanked by two carbonyl groups is critical to Cerulenin’s 
inhibitory activity, in which a cysteine residue opens the epoxide at C-2 of hydroxyl lactam form, thus 
irreversibly deactivating the β-ketoacyl synthase (figure 12).94b, 95 
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Figure 13. Open and closed form of cerulenin 
 
 
Figure 14. Cysteine opening of cerulenin's epoxide functionality 
 
Likewise, we are interested in cerulenin analogues as a potential tool for elucidating the 
mechanism of protein complexes that can be derived from that of FASN. Various attempts of 
structure activity studies have been performed to find out which parts of the molecule are important 
and should be developed for a more efficient and selective inhibition towards target protein. Thus, 
developing chemically more stable synthetic derivatives is also important due to the cytotoxicity of 
cerulenin having pharmacological limitations. By constructing novel inhibitor derived from cerulenin 
might give revolutionary effect on drug market. 
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II. RESULTS AND DISCUSSION 
Cerulenin has previously been shown to inhibit the fatty acid synthesis and protein 
palmitoylatoin96. The epoxycarboxamide moiety of cerulenin has been proposed as the warhead of the 
compound, which alkylates the cysteine residues in fatty acid synthase (FASN) and palmitoyl 
acyltransferases, leading to irreversible inhibition.97 In light of the interesting inhibitory properties 
displayed by cerulenin, we were keen to explore the possible binding mode of this natural product 
with a view to design various derivatives that would be amicable to synthetic manipulation in order to 
enable SAR studies. Therefore, assuming that a similar cysteine-based epoxide opening mechanism 
can be observed with that of FASN, designing cerulenin analogues could be performed for inhibiting 
enhanceosomes which are related to inflammation. Recent studies have shown that DNA bound NF-
κB initiates the formation of distinct enhanceosomes in a target gene-specific manner.98 When the cell 
is infected by viruses or other stimulus, several different DNA-binding proteins are produced, 
including TonEBP, transcriptional cofactor p300, and NF-κB (p65) which shown to act crucial role in 
inflammation.99 Furthermore, the compelling evidence that cerulenin prevents inflammation by 
specifically disrupting the p65-TonEBP-p300 interaction offers a promising target for useful anti-
inflammatory agents. 
Not only designing analogues but also from the basis of these results, we can hypothesize that a 
clickable long chain analogue of cerulenin might serve as a chemical probe to investigate its cellular 
targets and directly label the binding proteins in vitro and in cells. Click chemistry reaction is the most 
widely employed reaction in biological studies. The copper(I)-catalyzed reaction is mild and very 
efficient, requiring no protecting groups, and no purification in many cases.100The coupling reaction 
of azide and alkyne groups which form a very stable triazole ring as a linker, is largely inert towards 
biological molecules and aqueous environments, which allows the use of the Huisgen 1,3-dipolar 
cycloaddition in target guided synthesis101 and activity-based protein profiling.102 After, by using 
biotin-streptavidin, we can easily fish out the target protein from protein complexes. From this effort, 
we can dissect new cellular targets of cerulenin analogues which are considered as potent inhibitor of 
inflammatory activity. We therefore, synthesized clickable analogues of cerulenin which has an alkyne 
group that can act as a chemical probe to explore accumulation of target proteins of interest. By using 
click chemistry of copper catalyzed azide-alkyne cycloaddition, we can selectively tag the target 
protein by a covalently bond with cerulenin epoxide group with a cysteine residue. Taken together, 
identification of the target protein of NF-κB enhanceosome may shed light on the detailed mechanism 
of inhibition by cerulenin, which could provide a basis for the discovery of new therapeutic agents.  
 
2.1. Preparation of the click compound.  
Monoalkylation of diol 1 using sodium hydride gave alkynol 2. Alkynol 2 reacted with a excess 
of 1,6-dibromohexane with sodium hydride in the presence of a catalytic amount of 
28 
tetrabutylammonium bromide (TBAB) afforded the bromoether 3 in good yield.103 Alkynol 4 was 
synthesized by reacting with diol on to the alkyl bromide 3. Parikh–Doering oxidation (SO3·pyr, 
DMSO) of the alcohol 4 afforded aldehyde 5.104 Aldehyde 5 was reacted with vinylmagnesium 
bromide to give secondary alcohol 6. Reaction of the acryloyl chloride with the racemic alcohol 6 in 
the presence of Hunig’s base gave the acryloyl ester 7. We then tried to make lactone 10 with olefin 
metathesis of 7 using Grubbs’ second-generation catalyst, but failed to have desired compound. We 
therefore decided to protect alkyne with dicobalt–octacarbonyl which forms very stable complexes 
with alkynes and also can be deprotected in mild oxidative condition. Fortunately, alkyne protection 
reaction with dicobalt–octacarbonyl105 lead to the desired cobalt hexacarbonyl protected ester 8 in 
quantitative yield. Ring-closing metathesis of bis olefinic ester 8 proceeded with Grubbs’ second 
generation catalyst 106 to furnish the α,β-unsaturated γ-lactone 9. Subsequently, cobalt-protected-
alkyne 9 was deprotected using NaOCl to regenerate the furanonic alkyne 10 in good yield. Highly 
efficient sodium hypochlorite olefin epoxidation of 10 afforded epoxy anhydride 11, which was 
converted to amide 12 by reacting with ammonia. Oxidation of the resulting secondary carbinol 12 
with TPAP/NMO provided ketone 13 in moderate yield. 
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Scheme 1. Reagents and conditions: a) NaH, Propargyl bromide, THF, 81%, b) NaH, 1,6-
dibromohexane, TBAB, THF, 59%, c) NaH, 1,4-butanediol, THF, 82%, d) SO3-Pyridine, TEA, 
DMSO/DCM, 78%, e) Vinyl magnesium bromide, THF, 44% f) Acryloyl chloride, DIPEA, DCM, 
66%, g) Co2(CO)8, DCM, 82%, h) Grubbs 2nd generation catalyst, DCM, 40%, i) NaOCl, 
pyridine,65%, j) NaOCl, pyridine, 55%, k) NH4OH, Methanol, 57%, l) NMO, TPAP, 4A° ms, DCM, 
40% 
 
For the synthesis of another click compound 20, the required alcohol 16 was prepared. 
Bromocarboxylic acid 14 was treated with lithium (trimethylsilyl)acetylide, which prepared by 
deprotection of trimethylsilylacetylene with butyllithium, to give compound 15 in 56% yield. 
Following reduction with lithium aluminum hydride and deprotection of the trimethylsilyl (TMS) 
group, desired alkynol 16 was obtained. (Scheme 2) The ester-amide 20 was prepared starting from 
the known epoxy maleic anhydride. Sodium tungstate catalyzed epoxidation of maleic acid or its 
anhydride gave the disodium salt in 99% yield on a molar scale, which was converted to carboxylic 
acid 17 via the corresponding barium salt in 75-80% overall yield.107 The anhydride 18108 was formed 
by heating 17 with 2 equivalents of TFAA in dichloromethane. Ring opening of anhydride 18 was 
achieved by reacting with the alkynol 16 to give the mono substituted ester-acid 19 in good yield. 
Attempts to make amide 20 by employing coupling reaction such as DCI and DMAP, and oxalyl 
chloride did not give the desired compound. At last, the carboxamide 20 was prepared by activating 
the ester-acid with PCl5 and then quenching the intermediate acid chlorides with NH3 gas to give the 
ester-amide 20.  
 
Scheme 2. Reagents and conditions: a) (CH3)3SiC≡CH, BuLi, THF, - 78℃ 57%, b) LiAlH4, THF then 
TBAF, 93% 
 
 
Scheme 3. Reagents and conditions: a) TFAA, DCM, quantitative, b) 16, TEA, DCM, 79%, c) 
(COCl)2, DMF, NH4OH, DCM, d) DIC, DMAP, NH3, DCM, e) PCl5, DCM, then NH3 (g), 83% 
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2.2. Preparation of the cerulenin analogues  
To further increase the scope of the structural diversities of cerulenin derivatives, we designed 
compounds containing cis epoxide flanked by dicarbonyl groups, while bearing various side chains 
and head units. As the active form of cerulenin in biological system is unknown, we aimed to resolve 
this question by exploring binding mode of our synthesized analogues. Therefore, we synthesized 
analogues which mimic cerulenin structure but replacing the ketone with ester, amide, thioester and 
sulfone. In order to expedite synthesis and biological evaluation of molecules corresponding to the 
designed inhibitors, cerulenin analogues we decided to prepare the inhibitors as racemates.  
Ester acid 21 and ester amides 22, 23 were synthesized by the same procedure for ester-amide 20. 
Esterification of anhydride 18 was achieved by reacting with the appropriate alcohol to give the mono 
substituted ester-acids 21a-f in good yields (Scheme 4). The carboxamide series 22 was prepared by 
activating the ester-acids with PCl5 and then quenching the intermediate acid chlorides with NH3 to 
give the desired ester-amides 22a-f in moderate yields. 23a-c was prepared in same manner of 22 but 
with appropriate amines having different substitute at the amide function. This route is short and ideal 
for analogue synthesis with the potential to add more complex and various side chains as a last step. 
 
Scheme 4. Reagents and conditions: a) R-OH, TEA, DCM, 98%, b) PCl5, DCM, c) NH3 (g), 40-70%, 
d) R-NH2, 30-90% 
 
Tabel 1. R, R1, R2 group substituent on scheme 4 
 
31 
In addition, the ester alcohol 25 was readily prepared by esterifcation of the known meso-epoxy 
diol 24 prepared by m-CPBA epoxidation of cis-butene-1,4-diol.(Scheme 5).109 Ester acid 26 was 
prepared by oxidation of the epoxy alcohol 25 with RuCl3 to the acid and subsequent amide formation 
using gaseous ammonia to have 27 in hand. 
 
 
Scheme 5.Reagents and conditions: a) Octanoyl chloride, Pyridine, DMAP, DCM, 44%, b) NaIO4, 
RuCI3·H2O, H2O/ACN/EA, 39%, c) PCl5, DCM, then NH3 (g), 77% 
 
Another functional analogue of cerulenin which we prepared was the diamide 30. We first tried 
to make amide-acid by directly reacting anhydride 18 with octylamine to prepare diamide, but did not 
work out. Next, we then prepared acid amide to react with octylamine to make diamide, but the acid-
amide failed to react with octylamine. Because of difficulties encountered with the synthesis of 
structure 30, we tried alternative route to prepare 30 which are discussed below. (Scheme 6) Thus, 
aliphatic amide-ester 29 was to start from the ester-acid 28, activate with PCl5, and quench with 
octylamine. Ester-acid 28 was obtained by simply heating anhydride 18 with neat methanol. 
Treatment of 29 with methanolic ammonia gave the diamide 30.  
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Scheme 6. Reagents and conditions: a) Octylamine, DCM, b) Hexamethyldisilazane, THF, c) 
Octylamine, EDCI, HOBT, DMF, d) MeOH, quantitative, e) Octylamine, DIC, DMAP, DCM, f) N-
methylmorpholine, Isobutyl chloroformate, Octylamine, Ether, g) Octylamine, EDCI, HOBT, DCM, h) 
PCl5, DCM, then Octylamine, TEA, RT, i) PCl5, DCM, then octylamine, TEA, -20°C, 58%, j) 
NH4OH(aq), MeOH, 85%, 
 
The third series of target molecules were the carboxamides that have thioester and sulfone in the 
opposite side. Ring opening of anhydride 18 with thiol and DMAP in acetonitrile/pyridine solution 
successfully gives the thioester-acid 31 in moderate yield. Thioester-amide 32 was prepared in a 
similar manner of the ester-amide 20 in moderate yield. (Scheme 7) 
 
 
Scheme 7. Reagents and conditions: a) CH3(CH2)9SH, DMAP, ACN:Pyridine (9:1), 60%, b) PCl5, 
DCM, then NH3 (g), 62% 
 
Copper-catalyzed conjugate addition of thiol to methylpropiolate 33, which proceeds through an 
allenolate intermediate gave mixture of stereoselective isomers 34 and 35 in 42% and 20% yield (Z/E 
=60/40).110 Oxidation of the Z-vinyl sulfide 34 with excess sodium perborate gave sulfone 36 in 
moderate yield. Stereoselective oxidation to the epoxide 37 was effected following the procedure 
described by Hegedus et al.111 The methyl ester 37 was hydrolyzed by LiOH-H2O to give acid 38 in 
almost quantitative yield. Amidation of 38 with same procedure using ammonia led to sulfonyl amide 
39. (Scheme 8) 
 
 
Scheme 8. Reagents and conditions: a) CH3(CH2)9SH, CuCl, K2CO3 DMSO, 62%, b) NaBO3, AcOH, 
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50%, c) NaClO, Et2O:DMF (1:1), 70%, d) LiOH·H2O, THF:H2O (2:1), 68%, e) PCl5, DCM, then 
NH3(g), 60% 
 
Lastly, we synthesized michael acceptor compound 42 having olefin, which is different from 
other analogues having epoxide moiety. We anticipated that cysteine residues of enhanceosome can 
undergo Michael additions with 42, showing similar binding mechanism of epoxide function. 
Esterification of maleic anhydride 40 over alcohol gave acrylic acid 41. Amidation of 41 with in the 
presence oxalyl chloride and DMF as a catalyst gave ester-amide 42. (Scheme 9) 
 
Scheme 9. Reagents and conditions: a) 1-octanol, TEA, DCM, 20%, b) (COCl)2, DMF, DCM, then  
NH4OH, 34 %  
 
2.3. Structure activity relationship (SAR) 
Potent analogues of cerulenin, with various chain lengths and substitutions, are synthesized for 
use in SAR studies. The cerulenin analogues were evaluated for their ability to inhibit enhanceosome 
in two assays, NO (nitric oxide) assay and MTS assay in order to derive SAR. The NO assay 
determines quantitative nitrite (NO2-) production of the compounds in biological fluids. As Nitric 
oxide (NO) plays an important role in inducing inflammation, it has been observed that the 
overproduction of nitric oxide causes dysfunction of several organs and affects lactate level. Therefore, 
we tried this assay to see the inhibitory activity of cerulenin analogues towards nitrite production by 
LPS-activated macrophages quantified nitrite in the culture medium using Griess reagent. Comparing 
nitrite production of Cerulenin derivatives with Cerulenin could screen out inhibitory activity of 
inflammation. Another assay, MTS assay is a sensitive colorimetric assay for quantification of the 
number of viable cells in the proliferation and cytotoxicity. As cell viability is important for analysis 
of many pharmaceutical compounds and drugs, the MTS assay considered the most economic, reliable 
and convenient methods for showing cytotoxicity in vitro to assess for cell viability.  
The effects of the cerulenin and its analogues on NO production were determined by NO assay. 
(Table 2) Among others, 22d, 22e and 42, a chain length consisting of more than eight carbons, 
showed similar inhibition of NO production with that of cerulenin. This indicates that the longer 
hydrophobic side chain might afford better inhibition of NO production, giving positive effects on 
inhibiting enhanceosome. Meanwhile, the shorter analogues 22b and 22c give moderate inhibition but 
not sufficient than that of cerulenin. The other epoxysuccinamate esters 22a and 22f which have 
branched form of the side chain did not seem to inhibit NO production as well as cerulenin because of 
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the steric effect of the molecule with binding of the protein. Moreover, other aliphatic analogues 
display a rather high range of NO production depending on functionalities surrounding the epoxide 
moiety. Amide ester 29, thioester 32 and sulfone 39 did affected inhibition of NO production, but not 
as satisfying as other analogues that were mentioned above. Furthermore, octyl ester amide analogues 
23a-23c with different substituents at the amide moiety did not give satisfying result in reducing NO 
formation. Other analogues 21d, 27 and 30 also showed less inhibition of NO than cerulenin and other 
analogues. For the click compound 20 also did not appear to be the essential molecules for inhibiting 
NO production, but 13 successfully inhibit NO formation more than any other analogues including 
cerulenin itself. Overall, we cannot assure that which analogue is the most potent for inhibiting NO 
production, but most of the epoxycarboxamide analogues that we synthesized successfully inhibit the 
inflammatory process. Interestingly, from the results of the NO production of some analogues, it 
seems likely that the open straight chain form of the cerulenin analogues can be considered as active 
conformation when binding with cysteine residue of the protein which was an unrevealed issue.  
 
Table 2. Inhibition of NO production in RAW 264.7 cells by cerulenin and its analogues 
Compound Inhibition of NO 
production(µM) 
Compound Inhibition of NO 
production(µM) 
cerulenin 4.1 23c >20 
21d >20 27 >20 
22a >20 29 13 
22b 6.6 30 >20 
22c 6.9 39 9.9 
22d 3.8 32 11.8 
22e 4.6 42 5 
22f 15 
  
23a >20 20 16 
23b >20 13 0.9 
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Figure 15. Inhibition of NO production in RAW 264.7 cells by cerulenin and its analogues. 
 
Cytotoxicity testing of cerulenin and its analogues were performed using RAW 264.7 cells with 
LPS. The results obtained with the MTS assay (figure 2) demonstrate all of the synthesized aliphatic 
analogues 20-42 have similar cytotoxicity with cerulenin. Cell viability based on reduction of MTS 
indicates the high cell survival of analogues similar to cerulenin. From this result, the analogues that 
we synthesized are considered to be are essentially nontoxic. Moreover, the cytotoxicity of the 
analogues appears to be independent from chain length and other functionalities surrounding the 
epoxide moiety. However, the click compound 13 which showed greatest inhibition of NO production 
displayed low percentage of surviving cells, but somehow can be considered as mild survival rate.  
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Figure 16. Effect of cerulenin and its analogues with concentration of 10 µM on the cell viability of 
RAW 264.7 cells 
 
Additionally, we tried fatty acid synthase activity assay with several analogues of cerulenin 
including the click compound 13 to see whether the inhibitory activity towards fatty acid synthase 
(FASN) is same as cerulenin. Because cerulenin and certain of its analogues are known to inhibit 
FASN, the inhibitory activity of the synthesized compounds against FASN has been determined. 
(Figure 3) To compare the efficacies of various compounds towards FASN, data was indicated in 
percentage by which fatty acid synthesis is reduced in samples treated with 10 µM of the indicated 
analogues and 13 with a dose of 7.5 µM. As expected, cerulenin effectively inhibited the tumor cell 
fatty acid synthase activity. Greatest inhibition was occurred with 13 showing similar pattern with 
cerulenin. However, cerulenin analogues showing contentable inhibition of NO production had no 
significant inhibitory effects on fatty acid synthesis. Likewise, these compounds are essentially 
inactive against fatty acid synthase but inhibit inflammatory response, meaning that the target for the 
inhibitory activities of the cerulenin analogues is clearly distinguished from that of cerulenin. 
Therefore, the analogues that we synthesized are more closely associated with inhibition of other 
protein that is related to inflammation than with suppression in the fatty acid synthesis. More 
interestingly, from the result that the open side chain analogues don’t inhibit FASN unlike molecules 
that can form hydroxylactam, we have learn that the structure of inhibitors play a crucial role in 
targeting specific protein related to inflammation. 
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Figure 17. Inhibition of Fatty acid synthase activity in RAW 264.7 cells by cerulenin and its 
analogues with concentration of 10 µM 
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III. CONCLUSION 
Cerulenin offers an attractive opportunity to develop new class of effective and safe anti-
inflammatory agents. We have designed and synthesized several analogues of the natural product 
cerulenin with varying chain lengths and substitutions, which can be considered as promising 
candidates for the anti-inflammation therapeutic molecule. Assaying of these compounds revealed that 
a significant decrease in NO production and low cytotoxicity could be achieved by the derivatives 
with epoxycarboxamide moiety similar to that displayed by cerulenin. In addition, comparing the 
activity of cerulenin and its analogues towards FASN, we have discovered that synthesized analogues 
are more closely related to inhibition of other protein associated with inflammation than with 
suppression in the fatty acid synthesis. From these result, we have also learned that the structure of 
inhibitors play a crucial role in targeting specific protein related to inflammation. As such 
differentiation is displayed, the clickable analogue of cerulenin could be used as a chemical probe to 
explore the target protein. Still, more work is needed in order to optimize the structures of these 
inhibitors as potential anti-inflammatory drug leads.  
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IV. EXPERIMENTAL 
General methods: All the reactions were carried out in a flame or oven dried glassware under 
nitrogen atmosphere with freshly distilled dry solvents under anhydrous conditions unless otherwise 
indicated. Flash column chromatography was performed with silica gel 60 (230 – 400 mesh). 
Chromatograms were visualized by fluorescence quenching with UV light at 254 nm or by staining 
using base solution of potassium permanganate and molybdate. All reagents were obtained from 
commercial sources and were used without further purification. Proton (1H) and carbon (13C) NMR 
spectra were recorded on a 300 / 75 MHz Bruker DPX300 Fourier transform spectrometer. The 
residual solvent signals were taken as the reference (0.0 ppm for 1H NMR spectra and 77.0 ppm for 
13C NMR spectra in CDCl3) Chemical shift (δ) is reported in ppm, coupling constants (J) are given 
in Hz. The following abbreviations classify the multiplicity: s = singlet, d = doublet, t = triplet, m = 
multiplet, dd = doublet of doublet, q = quartet and br = broad signal. Samples were prepared in 
deuterated chloroform (CDCl3) as indicated. Solvents for this purpose were obtained from Cambridge 
Isotope Laboratories, Inc. LC-MS analysis was carried out using an Agilent Technologies 1200 series 
HPLC coupled to a Bruker HCT Ultra mass spectrometer.  
 
Synthetic Procedures: 
 
4-(prop-2-ynyloxy)butan-1-ol (2). To the solution of Sodium hydride (3.2 g, 110.96 mmol) in 
anhydrous THF (50 mL) was added 1,4-butanediol (10 g, 110.96 mmol) in THF dropwise at 0 oC 
under N2 atmosphere. After stirring for 45 minutes, propargyl bromide (1 mL, 77.67 mmol) in THF 
(20 mL) was add to the mixture drop wise. After completion of reaction by TLC monitoring in 9h, 
reaction mixture was quenched by cold water (5 mL) and aqueous layer was extracted with Ethyl 
acetate (2 x 15 mL). Combined organic layer was washed with brine solution (15 mL) and dried over 
Na2SO4 filtered, concentrated under reduced pressure. Crude was Purification by Column 
chromatography using 20% EtOAc/Hexane. Obtained pure compound 2 in 81% yield; 1H NMR (400 
MHz, CDCl3) δ 4.13 (d, J = 2.4, 2H), 3.63 (t, J = 6.0, 2H), 3.54 (t, J = 5.9, 2H), 2.42 (t, J = 2.4, 1H), 
1.66 (m, 4H); 13C NMR (400 MHz, CDCl3) δ 79.65, 74.35, 69.99, 62.47, 58.04, 29.69, 26.16; ESI-MS 
m/z calculated for C7H12O2 [M + H]+: 129.1; Found:129.2 
 
 
1-bromo-6-(4-(prop-2-ynyloxy)butoxy)hexane (3). To the solution of Sodium hydride (4.49 g, 
112.35 mmol) in anhydrous THF (75 mL) was added 1-butanol, 4-(2-propynyloxy) (12 g, 93.62 mmol) 
in THF (25 mL) at 0oC under N2 atmosphere. After stirring for 30 min, 1,6-dibromohexane (43.2 mL, 
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280.87 mmol) in THF (50 mL) was added dropwise, followed by catalytic TBAB (5 mol%) was 
added at 0 oC. The reaction mixture was stirred for 13 h. After completion of reaction by TLC 
monitoring, reaction was quenched by Ammonium chloride (25 mL) and aqueous layer was extracted 
with Ethyl acetate (2 x 50 mL). Combined organic layers was washed with brine solution (50 mL) and 
dried over Na2SO4 filtered, concentrated under reduced pressure. Crude was purified by Column 
chromatography using 2% EtOAc/Hexane. Obtained pure compound 3 in 70% yield; 1H NMR (400 
MHz, CDCl3) δ 4.13 (dd, J = 2.3, 1.2, 2H), 3.53 (t, J = 5.7, 2H), 3.40 (m, 6H), 2.41 (t, J = 2.3, 1H), 
1.86 (qu, J = 6.9 , 2H), 1.65 (m, 4H), 1.57 (q, J = 6.7, 2H), 1.41 (m, 4H); 13C NMR (400 MHz, CDCl3) 
δ 79.98, 74.05, 70.62, 70.47, 69.91, 57.98, 33.87, 32.72, 29.55, 27.98, 26.35, 26.26, 25.40; ESI-MS 
m/z calculated for C13H23BrO2 [M + H]+: 291.1 ; Found: 291.2 
 
 
4-(6-(4-(prop-2-ynyloxy)butoxy)hexyloxy)butan-1-ol (4). To the solution of Sodium hydride (0.3 g, 
12.1 mmol) in anhydrous THF (8 mL) was added drop wise 1,4-butanediol (1.1g, 12.1 mmol) at 0oC 
under N2 atmosphere. After stirring reaction mixture for 30 min, bromo compound 3 (1.16 g, 4.02 
mmol) in THF (3 mL) was added to the mixture dropwise. Reaction mixture was stirred for 4h at 
room temperature. Upon reaction completed, reaction mixture was quenched by Ammonium Chloride 
(2 mL) and aqueous layer was extracted was extracted with ethyl acetate (2 x 10 mL). Combined 
organic layer was washed with brine solution and dried over Na2SO4 filtered, concentrated under 
reduced pressure. Crude was purified by Column chromatography using 25% EtOAc/Hexane system. 
Obtained pure compound 4 in 82% yield; 1H NMR (400 MHz, CDCl3) δ 4.14 (dt, J = 2.4, 0.5, 2H), 
3.63 (t, J = 5.6, 2H), 3.54 (bt, 2H), 3.42 (m, 8H), 2.61 (bs, 1H) 2.42 (td, J = 2.4, 0.5, 1H), 1.66 (m, 
8H), 1.57 (qu, J = 7.0, 4H), 1.36 (m, 4H); 13C NMR (400 MHz, CDCl3) δ 79.93, 74.09, 70.98, 70.81, 
70.75, 70.39, 69.88, 62.60, 57.93, 30.30, 29.63, 29.53, 26.88, 26.30, 26.21, 25.99, 25.96; ESI-MS m/z 
calculated for C17H32O4 [M + H]+: 301.2; Found:301.2 
 
 
4-(6-(4-(prop-2-ynyloxy)butoxy)hexyloxy)butanal (5). To the solution of alcohol 4 (1.63 g, 5.42 
mmol) in DCM (25 mL) at 0 °C was added triethylamine (1.89 mL, 13.57 mmol) followed by SO3-
Pyridine (2.16 g, 13.57 mmol) complex in DMSO (5 mL). The reaction mixture was stirred at 0 °C for 
4h. Upon reaction finished cold water (5 mL) was added. The DCM was removed under reduced 
pressure and extracted with diethylether (2 x 15 mL). The combined organic layers were washed with 
1M KH2PO4 (10 mL) and Brine solution (15 mL). The organic phase was dried over MgSO4 filtered, 
concentrated under reduced pressure. Crude was purified by Column chromatography using 15% 
EtOAc/Hexane system. Obtained pure compound 5 in 78% yield; 1H NMR (400 MHz, CDCl3) δ 9.78 
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(t, J = 1.6, 1H), 4.13 (d, J = 2.4, 2H), 3.53 (t, J = 6.2, 2H), 3.41 (m, 8H), 2.51 (td, J = 7.1, 1.6, 2H), 
2.41 (t, J =2.4, 1H), 1.91 (m, 2H), 1.65 (m, 4H), 1.55 (m, 4H), 1.34 (m, 4H); 13C NMR (400 MHz, 
CDCl3) δ 202.31, 79.99, 74.05, 70.92, 70.79, 70.43, 69.92, 69.55, 57.97, 40.96, 29.70, 29.62, 26.35, 
26.26, 26.03, 22.60; ESI-MS m/z calculated for C17H30O4 [M + H]+: 299.2; Found: 299.2 
 
 
6-(6-(4-(prop-2-ynyloxy)butoxy)hexyloxy)hex-1-en-3-ol (6). To the solution of aldehyde 5 (1.24 g, 
4.16 mmol) in anhydrous THF (15 mL) was added 1M solution of vinyl magnesium bromide (6.24 
mL, 6.24 mmol) in THF drop wise with vigorous stirring at -78 °C under nitrogen atmosphere. The 
reaction mixture was stirred at -78 °C for 4h then raised temperature to room temperature. Upon 
completion of reaction quenched with saturated ammonium chloride (2 mL) at 0 °C. The THF was 
removed under reduced pressure and extracted with diethyl ether (2 x 10 mL). The organic layer was 
washed with brine (10 mL), dried over anhydrous Na2SO4 filtered, concentrated under reduced 
pressure. Crude was purified by column chromatography using 15% EtOAc/Hexane. Obtained pure 
compound 6 in 44% yield; 1H NMR (400 MHz, CDCl3) δ 5.87 (ddd, J = 17.2, 10.4, 5.8, 1H), 5.24 (dd, 
J = 17.2, 1.5, 1H), 5.10 (dd, J = 10.4, 1.5, 1H), 4.14 (d, J = 2.4, 2H), 3.53 (m, 2H), 3.42 (m, 9H), 2.78 
(bd, 1H), 2.41 (t, J =2.4, 1H), 1.67 (m, 6H), 1.58 (m, 6H), 1.36 (m, 4H); 13C NMR (400 MHz, CDCl3) 
δ 141.20, 114.26, 79.97, 74.06, 72.56, 71.02, 70.90, 70.78, 70.41, 69.91, 57.96, 34.69, 29.66, 29.54, 
26.33, 26.24, 26.01, 25.98, 25.92; ESI-MS m/z calculated for C19H34O4 [M + H]+: 327.2; Found: 
327.2 
 
 
6-(6-(4-(prop-2-ynyloxy)butoxy)hexyloxy)hex-1-en-3-yl acrylate (7). To the acrylic acid (16 µl, 
0.24 mmol) in dry DCM (2 mL) was added oxalyl chloride (27 µl, 0.31 mmol) and 1 drop of DMF at 
0 °C. The reaction mixture was stirred for 30 min. To the acryloyl chloride reaction mixture was 
added allylic alcohol 6 (40 mg, 0.12 mmol) in DCM (1 mL) and DIPEA (51 µl, 0.36 mmol) at 0 °C 
under nitrogen atmosphere. The reaction mixture was stirred for 2h at 0 °C. Upon completion of 
reaction, solvent was removed under reduced pressure and purified by column chromatography using 
10% EtOAc/Hexane. Obtained pure compound 7 in 66% yield; 1H NMR (400 MHz, CDCl3) δ 6.41 
(dd, J = 17.3, 1.5, 1H), 6.13 (dd, J = 17.3, 10.4, 1H), 5.82 (dd, J = 10.4, 1.4, 1H), 5.34 (q, J = 6.3, 1H), 
5.26 (dt, J = 17.3, 1.3, 1H), 5.18 (dt, J = 10.5, 1.2, 1H), 4.13 (d, J = 2.4, 2H), 3.53 (bt, 2H), 3.39 (m, 
9H), 2.41 (t, J = 2.4, 1H), 1.73 (m, 2H), 1.65 (m, 4H), 1.57 (m, 6H), 1.35 (m, 4H) 
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Dicobalt-octacarbonyl protected acryloyl ester (8). To the solution of 7 (225 mg, 0.59 mmol) in 
Dry DCM (10 mL) was added Co2(CO)8 (222 mg, 0.65 mmol) under organ atmosphere at room 
temperature. The reaction mixture was stirred for 2h at room temperature. Upon completion of the 
reaction, solvent was removed under reduced pressure and crude was purified by column 
chromatography using 6% EtOAc/Hexane as eluent system and obtained pure compound 8 in 82% 
yield; 1H NMR (400 MHz, CDCl3) δ 6.41 (dd, J = 17.3, 1.2, 1H), 6.13 (dd, J = 17.3, 10.4, 1H), 6.03 (s, 
1H), 5.82 (d, J = 10.5, 1H), 5.34 (q, J = 6.3, 1H), 5.26 (d, J = 17.2, 1H), 5.18 (d, J = 10.5, 1H), 4.62 (s, 
2H), 3.61 (t, J = 5.8, 2H), 3.40 (m, 9H), 1.64 (m, 12H), 1.35 (dt, J = 7.0, 3.8, 4H) 
 
 
Dicobalt-octacarbonyl protected lactone (9). To the solution of 8 (210 mg, 0.32 mmol) in dry DCM 
(100 mL) was added Grubbs 2nd generation catalyst (32.5 mg, 20 mol%) at room temperature under 
nitrogen atmosphere. The reaction mixture was stirred for 3h. Upon completion of the reaction, 
solvent was removed under reduced pressure and crude was purified by column chromatography 
using 20% EtOAc/Hexane as eluent system and obtained pure compound 9 in 82% yield; 1H NMR 
(400 MHz, CDCl3) δ 7.46 (d, J = 5.7, 1H), 6.11 (dd, J = 5.6, 1.7, 1H), 6.03 (s, 1H), 5.08 (bs, 1H), 4.62 
(s, 2H), 3.61 (t, J = 5.6, 2H), 3.41 (m, 8H), 1.89 (m, 2H), 1.64 (m, 10H), 1.32 (m, 4H) 
 
 
5-(3-(6-(4-(prop-2-ynyloxy)butoxy)hexyloxy)propyl)furan-2(5H)-one (10). To the solution of 9 
(0.023 mmol) in dry Pyridine (1 mL) was added NaOCl (0.050 mmol) at 0 °C under nitrogen 
atmosphere. The reaction mixture was stirred at room temperature until the reaction was finished 
checked by TLC. Upon completion of reaction, solvent was removed under reduced pressure and 
crude was purified by column chromatography using 20% EtOAc/Hexane as eluent system and 
obtained pure compound 10 in 65% yield; 1H NMR (400 MHz, CDCl3) δ 7.46 (dd, J = 5.7, 1.5 1H),  
6.11 (dd, J = 5.7, 2.0, 1H), 5.09 (tt, J = 7.0, 1.9, 1H), 4.13 (d, J =2.4, 2H), 3.53 (bt, 2H), 3.41 (m, 8H), 
2.41 (t, J = 2.4, 1H), 1.73 (m, 2H), 1.65 (m, 4H), 1.55 (m, 6H), 1.35 (qu, J = 3.6, 4H) 
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4-(3-(6-(4-(prop-2-ynyloxy)butoxy)hexyloxy)propyl)-3,6-dioxabicyclo[3.1.0]hexan-2-one (11). To 
the solution of 10 (0.045 mmol) in dry pyridine (1 mL) was added NaOCl (0.113 mmol) at 0 °C under 
nitrogen atmosphere. The reaction mixture was stirred at room temperature for 3h. Upon completion 
of reaction, solvent was removed under reduced pressure and crude was purified by column 
chromatography using 15% EtOAc/Hexane as eluent system and obtained pure compound 11 in 55% 
yield; 1H NMR (400 MHz, CDCl3) δ 4.62 (bt, 1H) 4.13 (d, J =2.4, 2H), 3.99 (d, J = 2.5, 1H), 3.78 (dd, 
J = 2.5, 0.8, 1H), 3.53 (bt, 2H), 3.41 (m, 8H), 2.41 (t, J = 2.4, 1H), 1.72 (m, 2H), 1.65 (m, 4H), 1.57 
(m, 6H), 1.35 (qu, J = 3.5, 4H) 
 
 
(2S,3S)-3-((S)-1-hydroxy-5-(6-(4-(prop-2-ynyloxy)butoxy)hexyloxy)pentyl)oxirane-2-
carboxamide (12). To the solution of 11 (0.026 mmol) in dry MeOH (0.4 mL) was added NH4OH 
(0.01 mL) at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at room temperature 
for 4h. Upon completion of reaction, solvent was removed under reduced pressure and crude was 
purified by column chromatography using 50% EtOAc/Hexane as eluent system and obtained pure 
compound 12 in 57% yield; 1H NMR (400 MHz, CDCl3) δ 6.14 (s, 1H) 5.61 (s, 1H), 4.14 (d, J = 2.5, 
2H), 3.54 (m, 2H), 3.42 (m, 11H),  3.13 (dd, J = 7.7, 4.6, 2H), 2.42 (t, J = 2.4, 1H), 1.78 (m, 2H), 
1.65 (m, 4H), 1.57 (m, 8H), 1.35 (dt, J = 7.2, 3.5, 4H) 
 
 
(2S,3R)-3-(5-(6-(4-(prop-2-ynyloxy)butoxy)hexyloxy)pentanoyl)oxirane-2-carboxamide (13). To 
the solution of 12 (0.015 mmol) in dry DCM (2 mL) was added NMO (0.045 mmol), TPAP (5 mol%) 
and 4A° molecular sieves (25 mg) powder at room temperature under nitrogen atmosphere. The 
reaction mixture was stirred at room temperature for 4h. Upon completion of reaction, solvent was 
removed under reduced pressure and crude was purified by column chromatography using 50% 
EtOAc/Hexane as eluent system and obtained pure compound 13 in 40% yield; 1H NMR (400 MHz, 
CDCl3) δ 6.05 (s, 1H) 5.50 (s, 1H), 4.13 (d, J = 2.4, 2H), 3.52 (m, 4H), 3.40 (m, 6H), 2.74 (dt, J = 
17.4, 7.1, 1H), 2.60 (dt, J = 17.4, 6.8, 1H), 2.41 (t, J = 2.4, 1H), 1.62(m, 14H), 1.36 (m, 4H) 
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10-(Trimethylsilyl)dec-9-ynoic acid (15). To the solution of ethynyltrimethylsilane (0.1 mL, 0.75 
mmol) in dry THF (1 mL) was added dropwise BuLi (0.4 mL, 0.78 mmol) at -78 °C. After 15 min of 
stirring, dry DMPU (51 µL) was added and the reaction was stirred for 1 h at -78 °C. The solution of 
8-Bromooctanoic acid (67mg, 0.3 mmol) in THF (0.5 mL) was added dropwise. The reaction was 
slowly warm to room temperature and stirred overnight. The reaction was quenched with 1 N HCl to 
pH = 1~2 and extracted with ethyl acetate (2 mL × 3). The combined organic layers were dried over 
anhydrous Na2SO4, concentrated in vacuo. The residue was purified via silica gel column 
chromatography (3:7 EtOAc–Hexane with 1% AcOH) to yield the title compound (41 mg, 0.17 mmol, 
57%) as colorless liquid; 1H NMR (400 MHz, CDCl3) δ 2.35 (t, J = 7.5, 2H), 2.21 (t, J = 7.1, 2H), 
1.63 (m, 2H), 1.51 (qu, J = 6.5, 2H), 1.36 (m, 6H), 0.14 (s, 9H); 13C NMR (400 MHz, CDCl3) δ 
179.74, 107.55, 84.34, 33.95, 28.87, 28.66, 28.52, 28.49, 24.57, 19.79, 0.15; ESI-MS m/z calculated 
for C13H24O2Si [M - H]-: 239.2; Found: 239.2 
 
 
Dec-9-yn-1-ol (16). To the suspension of LiAlH4(6.2 mg, 0.16 mmol) in THF (0.45 mL) was added 
dropwise the solution of alkynoic acid 6a in THF (50 µL) at 0°C. The reaction was slowly warm to 
room temperature and stirred at room temperature for 3 h. After reaction completion monitored by 
TLC, the reaction mixture was cooled to 0 °C and slowly added H2O (50 µL) and 15% NaOH 
aq.solution (50 µL). More H2O (150 µL) was added and warm to room temperature and stirred at 
room temperature for 5 min. The precipitated solid was filtered through Celite and dried over Na2SO4 
and concentrated in vacuo. Combined filtrate was dissolved in the solution of TBAF (1.0 M, 0.32 
mmol) and stirred at room temperature for further 5 h. After the reaction was complete, the reaction 
mixture was concentrated in vacuo to dryness. The residue was purified via silica gel column 
chromatography (1:9 Acetone–DCM) to yield the title compound (23 mg, 0.15 mmol, 93%) as 
colorless liquid; 1H NMR (400 MHz, CDCl3) δ 3.64 (t, J = 6.4, 2H),  2.18 (td, J = 7.1, 2.6, 2H), 1.93 
(t, J = 2.6, 1H), 1.53 (m, 4H),  1.37 (m, 8H); 13C NMR (400 MHz, CDCl3) δ 84.72, 68.06, 63.03, 
32.75, 29.24, 29.03, 28.64, 28.43, 25.66, 18.36; ESI-MS m/z calculated for C10H18O [M + H]+: 155.1; 
Found: 155.2 
 
 
cis-2,3-Epoxysuccinic anhydride (18). cis-2,3-Epoxysuccinic acid (1.52 g, 11.5 mmol) was added to 
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a mixture of trifluororacetic anhydride (3.25 mL, 23.0 mmol) and dichloromethane (12 mL) and the 
resulting solution was stirred at 40 °C for 3 hours. The solvents were then removed under reduced 
pressure to yield the title compound (1.31 g, 11.51 mmol, quantitative) as a colourless prisms; 1H 
NMR (400 MHz, CDCl3) δ 4.31 (s, 2H ); 13C NMR (400 MHz, CDCl3) δ 162.30 (1-C and 4-C), 50.97 
(2-C and 3-C); ESI-MS m/z calculated for C4H2O4 [M -H]; 113.0; Found: 113.2 
 
General Method for Epoxysuccinic Ester-Acids 19, 21a-g. 
cis-2,3-Epoxysuccinic anhydride 18 (0.5 mmol, 1 eq), an appropriate distilled alcohol (0.6 mmol, 1.2 
eq) and triethylamine (0.75 mmol, 1.5 eq) were stirred in dichloromethane (2.5 mL) at room 
temperature for 1 hour. The excess alcohol and solvents were removed by evaporation at reduced 
pressure. The resulting residue was purified via column chromatography (4:1 EtOAc–hexane using 1% 
AcOH) to give quantitative yields of the desired compound. 
 
 
(2R,3S)-3-((dec-9-ynyloxy)carbonyl)oxirane-2-carboxylic acid (19). This compound was isolated 
as clear oil (79%); 1H NMR (400 MHz, CDCl3) δ 4.25 (td, J = 6.8, 2.5, 2H), 3.80 (d, J = 4.7, 1H), 
3.76 (d, J = 4.7, 1H),  2.19 (td, J = 7.0, 2.6, 2H), 1.94 (t, J = 2.6, 1H), 1.68 (qu, J = 6.8, 2H), 1.53 (dt, 
J = 14.6, 6.9, 2H),  1.34 (m, 10H); 13C NMR (400 MHz, CDCl3) δ 167.24, 166.95, 84.66, 68.14, 
37.18, 53.23, 52.87, 28.93, 28.85, 28.54, 28.35, 28.25, 25.56, 18.34 ; ESI-MS m/z calculated for 
C14H20O5 [M - H]: 267.1; Found: 267.2 
 
General Method for Epoxysuccinamate Esters 20, 22a-g. 
The following general method is exemplified by the procedure described below for the preparation of 
20, using the appropriate ester-acid 19 and other reagents scaled accordingly. 
 
O O
O
NH
2
O
 
(2S,3R)-dec-9-ynyl 3-carbamoyloxirane-2-carboxylate (20). PCl5 (136 mg, 1.08 mmol) was added 
in one portion to a chilled (-5 °C) solution of ester-acid 19 (220 mg, 0.9 mmol) in dichloromethane (5 
ml) at room temperature for 3 hours. After this time ammonia gas was added through pipet tubing by 
heating excess aq. NH4OH (10mL) in other flask with reflux condensed at 40 °C. After reaction 
completion monitored by TLC, the reaction mixture was filtered through a pad of Celite and washed 
with dichloromethane and concentrated to dryness. The resulting residue was purified via silica gel 
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column chromatography (1:1 EtOAc–Hexane) to yield the title compound (200 mg, 0.75 mmol, 83%) 
as a white solid; 1H NMR (400 MHz, CDCl3) δ 6.41 (bs, 1H), 5.48 (bs, 1H), 4.19 (td, J = 6.8, 1.9, 2H), 
3.73 (d, J = 5.0,  1H), 3.68 (d, J = 5.0, 1H), 2.19 (td, J = 7.0, 2.6, 2H), 1.94 (t, J = 2.6, 1H), 1.66 (qu, 
J = 6.7, 2H),  1.53 (m, 2H), 1.32 (m, 8H); 13C NMR (400 MHz, CDCl3) δ 167.49, 166.22, 84.64, 
68.15, 66.40, 54.48, 53.32, 28.95, 28.85, 28.54, 28.34, 25.58, 18.32; ; ESI-MS m/z calculated for 
C14H21NO4 [M + H]+: 268.1; Found: 268.2 
 
Epoxysuccinic Ester-Acids 21a-f. 
O
O O
OH
O
 
(2R,3S)-3-(isopropoxycarbonyl)oxirane-2-carboxylic acid (21a). This compound was isolated as 
yellowish oil (98%); 1H NMR (400 MHz, CDCl3) δ 5.14 (qu, J = 6.3, 1H), 3.77 (d, J = 4.8, 1H), 3.72 
(d, J = 4.8, 1H), 1.30 (dd, J = 11.5, 6.3, 6H); 13C NMR (400 MHz, CDCl3) δ 168.05, 166.31, 71.33, 
53.17, 52.97, 21.52; ESI-MS m/z calculated for C7H10O5 [M + H]+: 175.1; Found:175.2 
 
 
(2R,3S)-3-(butoxycarbonyl)oxirane-2-carboxylic acid (21b). This compound was isolated as 
yellowish oil (99%); 1H NMR (400 MHz, CDCl3) δ 4.26 (td, J = 6.7, 2.2, 2H), 3.79 (d, J = 4.7, 1H), 
3.76 (d, J = 4.7, 1H), 1.67 (dt, J = 14.7, 6.8, 2H), 1.39 (m, 2H), 0.95 ( t, J = 7.4, 3H); 13C NMR (400 
MHz, CDCl3) δ 166.75, 166.58, 66.69, 52.92, 52.88, 30.27, 18.86, 13.54; ESI-MS m/z calculated for 
C8H12O5 [M + H]+: 189.1; Found:189.2 
 
O
O
OH
O
O
 
(2R,3S)-3-(hexyloxycarbonyl)oxirane-2-carboxylic acid (21c). This compound was isolated as 
yellowish oil (98%); 1H NMR (400 MHz, CDCl3) δ 4.24 (td, J = 6.8, 1.8, 2H), 3.79 (d, J = 4.7, 1H), 
3.76 (d, J = 4.7, 1H), 1.68 (qu, J = 6.8, 2H), 1.31 (m, 6H), 0.89 ( t, J = 6.7, 3H); 13C NMR (400 MHz, 
CDCl3) δ 166.39, 166.70, 67.09, 53.02, 52.88, 31.26, 28.24, 25.29, 22.44, 13.93; ESI-MS m/z 
calculated for C10H16O5 [M + H]+: 217.1; Found: 217.2 
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(2R,3S)-3-(octyloxycarbonyl)oxirane-2-carboxylic acid (21d). This compound was isolated as 
yellowish oil (98%); 1H NMR (400 MHz, CDCl3) δ 4.23 (td, J = 6.8, 3.0, 2H), 3.78 (d, J = 4.7, 1H), 
3.75 (d, J = 4.7, 1H), 1.67 (qu, J = 6.8, 2H), 1.27 (m, 10H), 0.87 (br t, 3H); 13C NMR (400 MHz, 
CDCl3) δ 166.25, 166.74, 67.12, 53.05, 52.67, 31.71, 29.08, 29.07, 28.28, 25.63, 22.59, 14.04; ESI-
MS m/z calculated for C12H20O5 [M + H]+: 245.1; Found: 245.2 
 
 
(2R,3S)-3-(decyloxycarbonyl)oxirane-2-carboxylic acid (21e). This compound was isolated as 
yellowish oil (96%); 1H NMR (400 MHz, CDCl3) δ 4.23 (td, J = 6.8, 3.0, 2H), 3.78 (d, J = 4.7, 1H), 
3.75 (d, J = 4.7, 1H), 1.67 (qu, J = 6.8, 2H), 1.28 (m, 14H), 0.88 ( t, J = 6.6, 3H); 13C NMR (400 MHz, 
CDCl3) δ 167.18, 167.06, 67.32, 53.30, 52.87, 31.85, 29.47, 29.42, 29.25, 29.11, 28.28, 25.63, 22.65, 
14.08; ESI-MS m/z calculated for C14H24O5 [M + H]+: 273.2; Found: 273.2 
 
 
(2R,3S)-3-(((E)-3,7-dimethylocta-2,6-dienyloxy)carbonyl)oxirane-2-carboxylic acid (21f). This 
compound was isolated as yellowish oil (86%); 1H NMR (400 MHz, CDCl3) δ 5.35 (t, J = 7.3, 1H), 
5.07 (t, J = 6.7, 1H), 4.74 (m, 2H), 3.78 (d, J = 4.7, 1H), 3.75 (d, J = 4.7, 1H),  2.07 (m, 4H), 1.70 
(bd, J = 14.1, 6H), 1.60 (s, 3H); 13C NMR (400 MHz, CDCl3) δ 167.76, 166.84, 144.67, 132.04, 
123.50, 116.57, 63.73, 53.20, 52.91, 39.48, 26.17, 25.64, 17.68, 16.50; ESI-MS m/z calculated for 
C14H20O5 [M + H]+: 269.1; Found:269.2 
 
Epoxysuccinamate Esters, 22a-f 
O
O O
NH
2
O
 
(2S,3R)-isopropyl 3-carbamoyloxirane-2-carboxylate (22a). This compound was isolated as white 
solid (49%); 1H NMR (400 MHz, CDCl3) δ 6.43 (bs, 1H), 5.96 (bs, 1H), 5.08 (qu, J = 6.3, 2H), 3.68 
(d, J = 5.0, 1H), 3.65 (d, J = 5.1, 1H), 1.26 (dd, J = 16.8, 6.3, 6H); 13C NMR (400 MHz, CDCl3) δ 
167.27, 167.58, 165.66, 70.48, 54.42, 53.44, 21.61, 21.60; ESI-MS m/z calculated for C7H11NO4 [M + 
H]+: 174.1; Found:174.2 
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(2S,3R)-butyl 3-carbamoyloxirane-2-carboxylate (22b). This compound was isolated as white solid 
(43%); 1H NMR (400 MHz, CDCl3) δ 6.42 (bs, 1H), 5.70 (bs, 1H), 4.20 (t, J = 6.6 , 2H), 3.72 (d, J = 
5.0, 1H) and 3.67 (d, J = 5.0, 1H), 1.64 (dt, J = 14.7, 6.9, 2H), 1.38 (m, 2H), 0.93 ( t, J = 7.4, 3H); 13C 
NMR (400 MHz, CDCl3) δ 167.34, 166.23, 66.19, 54.48, 53.33, 30.38, 18.90, 13.58; ESI-MS m/z 
calculated for C8H13NO4 [M + H]+: 188.1; Found:188.2 
 
O
O
NH
2
O
O
 
(2S,3R)-hexyl 3-carbamoyloxirane-2-carboxylate (22c). This compound was isolated as white 
waxy solid (61%); 1H NMR (400 MHz, CDCl3) δ 6.41 (bs, 1H), 5.45 (bs, 1H), 4.19 (td, J = 6.8, 3.0, 
2H), 3.73 (d, J = 5.0, 1H) and 3.68 (d, J = 5.0, 1H), 1.66 (dt, J = 13.9, 6.8, 2H), 1.33 (m, 6H), 0.89 ( t, 
J = 6.8, 3H); 13C NMR (400 MHz, CDCl3) δ 167.51, 166.23, 66.49, 54.48, 53.34, 31.28, 28.33, 25.32, 
22.45, 13.94; ESI-MS m/z calculated for C10H17NO4 [M + H]+: 216.1; Found:216.2 
 
(2S,3R)-octyl 3-carbamoyloxirane-2-carboxylate (22d). This compound was isolated as white solid 
(72%); 1H NMR (400 MHz, CDCl3) δ 6.42 (bs, 1H), 5.50 (bs, 1H), 4.19 (td, J = 6.8, 4.6, 2H), 3.73 (d, 
J = 5.0, 1H), 3.68 (d, J = 5.0, 1H), 1.66 (qu, J = 6.8, 2H), 1.29 (m, 10H), 0.88 (t, J = 6.8, 3H); 13C 
NMR (400 MHz, CDCl3) δ 166.27, 166.24, 66.51, 54.49, 53.33, 31.72, 29.09, 28.38, 25.67, 22.60, 
14.05; ESI-MS m/z calculated for C12H21NO4 [M + H]+: 244.1; Found: 244.2 
 
 
(2S,3R)-decyl 3-carbamoyloxirane-2-carboxylate (22e). This compound was isolated as white solid 
(50%); 1H NMR (400 MHz, CDCl3) δ 6.41 (bs, 1H), 5.48 (bs, 1H), 4.19 (m, 2H), 3.73 (d, J = 5.0, 1H) 
and 3.68 (d, J = 5.0, 1H), 1.66 (qu, J = 6.8, 2H), 1.28 (m, 14H), 0.88 ( t, J = 6.8, 3H); 13C NMR (400 
MHz, CDCl3) δ 167.27, 166.24, 66.52, 54.50, 53.34, 31.85, 29.48, 29.44, 29.26, 29.13, 28.38, 25.67, 
22.65, 14.09; ESI-MS m/z calculated for C14H25NO4 [M + H]+: 272.2; Found:272.2 
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 (2S,3R)-((E)-3,7-dimethylocta-2,6-dienyl) 3-carbamoyloxirane-2-carboxylate (22f). This 
compound was isolated as white solid (65%); 1H NMR (400 MHz, CDCl3) δ 6.42 (bs, 1H), 5.55 (bs, 
1H), 5.33 (t, J = 7.3,  1H), 5.07 (t, J = 6.1,  1H), 4.76 (dd, J = 12.2, 7.3, 1H), 4.66 (dd, J = 12.2, 7.2, 
1H), 3.73 (d, J = 5.0, 1H), 3.67 (d, J = 5.0, 1H),  2.07 (m, 4H), 1.70 (bd, J = 8.9, 6H), 1.60 (s, 3H); 
13C NMR (400 MHz, CDCl3) δ 167.45, 166.17, 144.09, 131.99, 123.51, 116.91, 63.06, 54.51, 53.37, 
39.47, 26.19, 25.65, 17.68, 16.50; ESI-MS m/z calculated for C14H21NO4 [M + H]+: 268.1; 
Found:268.2 
 
General Method for Epoxysuccinamate Esters 23a-c. 
The following general method is exemplified by the procedure described below for the preparation of 
23a, using the ester-acid 21d and appropriate amine scaled accordingly. 
 
(2S,3R)-octyl 3-(methylcarbamoyl)oxirane-2-carboxylate (23a). PCl5 (50 mg, 0.39 mmol) was 
added in one portion to a chilled (-5 °C) solution of ester-acid 21d (80 mg, 0.33 mmol) in 
dichloromethane (3 ml) at room temperature for 3 hours. After this time methylamine hydrochloride 
(30 mg, 0.43 mmol) and triethylamine (0.14 mL, 0.99 mmol) were added slowly at room temperature 
for additional 2 hours. After reaction completion monitored by TLC, the reaction mixture was 
concentrated by evaporation at reduced pressure. The resulting residue was purified via silica gel 
column chromatography (1:1 EtOAc–Hexane) to yield the title compound (36mg, 0.14 mmol, 42%) 
as white solid; 1H NMR (400 MHz, CDCl3) δ 6.44 (bs, 1H), 4.16 (m, 2H), 3.69 (bd, 2H), 2.81 (d, J = 
5.0, 3H), 1.63 (dt, J = 13.9, 6.7, 2H), 1.29 (m, 10H), 0.87 (bt, 3H); 13C NMR (400 MHz, CDCl3) δ 
166.30, 165.24, 66.37, 54.78, 53.39, 31.72, 29.10, 29.08, 28.40, 25.65, 22.59, 14.04; ESI-MS m/z 
calculated for C13H23NO4 [M + H]+: 258.2; Found: 258.2 
 
 
(2S,3R)-octyl 3-(dimethylcarbamoyl)oxirane-2-carboxylate (23b). This compound was isolated as 
white solid (95%); 1H NMR (400 MHz, CDCl3) δ 4.15 (m, 2H), 3.76 (d, J = 4.6, 1H), 3.69 (d, J = 4.6, 
1H), 3.17 (s, 3H), 2.94 (s, 3H), 1.63 (qu, J = 6.8, 2H), 1.29 (m, 10H), 0.86 (bt, 3H); 13C NMR (400 
MHz, CDCl3) δ 166.63, 164.12, 66.06, 54.55, 52.64, 36.47, 35.31, 31.74, 29.14, 29.12, 28.40, 25.68, 
22.60, 14.05; ESI-MS m/z calculated for C14H25NO4 [M + H]+: 272.2; Found: 272.2 
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(2S,3R)-octyl 3-(hydroxycarbamoyl)oxirane-2-carboxylate (23c).This compound was isolated as 
white solid (30%); 1H NMR (400 MHz, CDCl3) δ 9.10 (bs, 1H, OH), 4.19 (m, 2H), 3.77 (d, J = 4.7, 
1H), 3.72 (d, J = 4.7, 1H), 1.66 (qu, J = 6.8, 2H), 1.28 (m, 10H), 0.88 (t, J = 6.8, 3H); 13C NMR (400 
MHz, CDCl3) δ 166.19, 163.07, 66.85, 53.35, 53.03, 31.72, 29.09, 28.30, 25.66, 22.59, 14.04; ESI-
MS m/z calculated for C12H21NO5 [M + H]+: 260.1; Found: 260.2 
 
 
((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methyl octanoate (25). Epoxy diol (0.14 g, 1.32 mmol), 
pyridine (0.2 ml, 2.64 mmol) and DMAP (16 mg, 0.13 mmol) were dissolved in dichloromethan
e (7 ml) and cooled to - 5°C. Octanoyl chloride (0.23 ml, 1.32 mmol) was added dropwise ove
r 15 min keeping the temperature below 5°C. The reaction was allowed to warm to room 
temperature and stirred for 5 hours. After TLC monitoring, the reaction mixture was quenched with 
ice water (0.1 mL). After stirring for 2~3 hours at room temperature, the solution was diluted 
with dichlromethane (2 ml), washed sequentially with 1M H2SO4 (3 x 2 ml), saturated NaHCO
3 (2 x 2 ml), dried over Na2SO4 and concentrated to dryness. The crude oil was purified via 
silica gel column chromatography (1:1 EtOAc–Hexane) to yield the title compound (135 mg, 0.58 
mmol, 44%) as yellow liquid; 1H NMR (400 MHz, CDCl3) δ 4.33 (dd, J = 12.2, 5.4, 1H),  4.15 (dd, J 
= 12.2, 5.6, 1H), 3.84 (bt, 2H),  3.23 (m, 2H), 2.36 (t, J = 7.5, 2H), 1.63 (qu, J = 7.5, 2H), 1.29 (m, 
8H), 0.87 (bt, 3H); 13C NMR (400 MHz, CDCl3) δ 173.99, 61.45, 6020, 56.08, 53.75, 34.07, 31.60, 
29.02, 28.86, 24.84, 22.56, 14.03; ESI-MS m/z calculated for C12H22O4 [M + H]+: 231.2 ; Found: 
231.2 
 
 
(2R,3R)-3-(octanoyloxymethyl)oxirane-2-carboxylic acid (26). suspension A was prepared prior to 
use; NaIO4 (0.5 g, 2.21 mmol) and RuCI3 ·  H2O (1.8 mg, 9 µmol) were suspended in H2O (1 mL) and 
stired at room temperature for 1 minute. Epoxy alcohol (51 mg, 0.22 mmol) was dissolved in 
Acetonitrile (2mL) and EtOAc (2 mL), cooled to 0°C and dropwise added suspension A over the 
course of 15 minutes. The flask containing suspension A was washed with H2O (0.5 mL), which was 
added the mixture over the course of 5 minutes. The mixture was left to stir at 0°C for 2 h. After TLC 
monitoring, the mixture was filtered through a pad of Celite and diluted with EtOAc (2 x 3 mL). The 
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organic phases were pooled in a separation funnel and added H2O (5 mL). After separation of the two 
phases the aqueous phase was extracted with EtOAc (2 x 6 mL). The pooled organic phases was 
washed with brine (6 mL), dried over MgSO4, filtered, concentrated in vacuo. The resulting residue 
was purified via silica gel column chromatography (1:1 EtOAc–Hexane with 1% 1AcOH) to yield the 
title compound (21 mg, 0.086 mmol, 39%) as colorless liquid; 1H NMR (400 MHz, CDCl3) δ 4.39 (dd, 
J = 12.4, 4.6, 1H),  4.27 (dd, J = 12.4, 6.4, 1H), 3.65 (d, J = 4.6, 1H), 3.49 (dt, J = 6.3, 4.6, 1H), 2.36 
(t, J = 7.6, 2H), 1.63 (qu, J = 7.5, 2H), 1.29 (m, 8H), 0.87 (bt, 3H); 13C NMR (400 MHz, CDCl3) δ 
173.72, 170.65, 60.98, 54.61, 51.38, 33.94, 31.90, 29.01, 28.85, 24.80, 22.56, 14.03; ESI-MS m/z 
calculated for C12H20O5 [M + H]+: 245.1; Found: 245.2 
 
 
((2R,3R)-3-carbamoyloxiran-2-yl)methyl octanoate (27). This compound was isolated as white 
solid (77%); 1H NMR (400 MHz, CDCl3) δ 6.24(bs, 1H), 5.62 (bs, 1H), 4.32 (dd, J = 12.6, 3.7, 1H), 
4.23 (dd, J = 12.6, 7.8, 1H), 3.59 (d, J = 4.8, 1H), 3.47 (ddd, J = 8.4, 4.6, 3.8, 1H),  2.37 (t, J = 7.6, 
2H), 1.64 (qu, J = 7.5, 2H), 1.29 (m, 8H), 0.87 (bt, 3H); 13C NMR (400 MHz, CDCl3) δ 173.55, 
168.47, 61.36, 54.98, 53.66, 33.97, 31.61, 29.02, 28.87, 24.80, 22.57, 14.04; ESI-MS m/z calculated 
for C12H21NO4 [M + H]+: 244.1; Found:244.2 
 
 
Monomethyl-cis-2,3-epoxysuccinate (28). cis-2,3-Epoxysuccinic anhydride 18 (93 mg, 0.82 mmol) 
was heated at 40°C in dry methanol (4 mL) for 17 hours. The excess alcohol was removed under 
reduced pressure to yield the desired compound (101 mg, 0.69 mmol, quantitative) which was used 
without further purification; 1H NMR (400 MHz, CDCl3) δ 3.87 (s, 3H), 3.80 (d, J = 4.7, 1H), 3.78 (d, 
J = 4.7, 1H); 13C NMR (400 MHz, CDCl3) δ 168.49, 166.84, 53.37, 52.82, 52.78; ESI-MS m/z 
calculated for C5H6O5 [M + H]+: 147.0; Found:147.2 
 
 
1-methyl-4-N-(4-octyl)-cis-2,3-epoxysuccinamate (29). PCl5 (24 mg, 0.19 mmol) was added in one 
portion to a chilled (-5 °C) solution of ester-acid 28 (23 mg, 0.16 mmol) in dichloromethane (1 ml) at 
room temperature for 3 hours. After this time 1-Octylamine (23 µl, 0.16 mmol) and tritylamine (24 µl, 
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0.24 mmol) were added at -20°C and stirred for 30 minutes. After reaction completion monitored by 
TLC, the reaction was quenched by the addition of acetic acid (28 ul, 0.47 mmol, 3 eq) at -20°C. The 
resulting residue was then concentrated to dryness and purified via silica gel column chromatography 
(3:7 EtOAc–Hexane) to yield the title compound (23 mg, 0.089 mmol, 58%) as a white solid; 1H 
NMR (400 MHz, CDCl3) δ 6.43 (bs, 1H), 3.78 (s, 3H), 3.72 (d, J = 5.0, 1H), 3.69 (d, J = 5.0, 1H),  
3.24 (m, 2H), 1.48 (qu, J = 7.2, 2H), 1.28 (m, 10H), 0.88 (t, J = 6.7, 3H); 13C NMR (400 MHz, CDCl3) 
δ 166.54, 164.38, 54.70, 53.33, 52.79, 39.14, 31.76, 29.33, 29.17, 29.15, 26.78, 22.61, 14.05; ESI-MS 
m/z calculated for C13H23NO4 [M + H]+: 258.2; Found: 258.2 
 
 
4-N-(4-octyl)-cis-2,3-epoxysuccinamide (30). The amide-ester 29 (15 mg, 0.058 mmol) was stirred 
with aqueous ammonia solution (0.1 mL, 2.56 mmol, excess) and methanol (0.5 ml) in room 
temperature for 3 hours. The resulting residue was then concentrated to dryness and purified via silica 
gel column chromatography (3:7 EtOAc–Hexane) to yield the title compound (12 mg, 0.049 mmol, 
85%) as a white solid; 1H NMR (400 MHz, CDCl3) δ 6.23 (bs, 1H), 5.51 (bs, 1H), 3.66 (d, J = 0.9, 
2H), 3.26 (m, 2H), 1.49 (qu, J = 6.9, 2H), 1.27 (m, 10H), 0.88 (t, J = 6.8, 3H); 13C NMR (400 MHz, 
CDCl3) δ 167.19, 164.79, 54.79, 54.59, 39.50, 31.75, 29.32, 29.15, 26.78, 22.60, 14.06; ESI-MS m/z 
calculated for C12H22N2O3 [M + H]+: 243.2;. Found: 243.2 
 
 
(2R,3S)-3-(decylthiocarbonyl)oxirane-2-carboxylic acid (31). To a stirred solution of cis-2,3-
Epoxysuccinic anhydride 18 (100 mg, 0.876 mmol) and DMAP (6 mg, 0.05 mmol) in 10 ml of 
acetonitrile-pyridine (9:1), Decanethiol (166 ul, 0.789 mmol) was added under argon. The mixture 
was allowed to stir at room temperature overnight before concentrating to dryness under reduced 
pressure, followed by dissolving the residue in EtOAc, and then washing with 1M HCl (3 x 5mL) and 
H2O (3 x 5mL) before drying over anhydrous MgSO4. The solution was concentrated under reduced 
pressure and dried in vacuo. The resulting residue was purified via silica gel column chromatography 
(1:1 EtOAc–Hexane with 1% AcOH) to yield the title compound (151 mg, 0.52 mmol, 60%) as 
colorless liquid; 1H NMR (400 MHz, CDCl3) δ 3.89 (d, J = 4.7, 1H),  3.81 (d, J = 4.7, 1H), 3.00 (td, 
J = 7.2, 2.1, 2H), 1.60 (qu, J = 7.3, 2H), 1.35 (m, 2H), 1.28 (m, 12H),  0.88 (t, J = 6.8, 3H); 13C 
NMR (400 MHz, CDCl3) δ 193.89, 167.78, 58.30, 54.12, 31.86, 29.49, 29.41, 29.35, 29.26, 28.99, 
28.95, 28.70, 22.65, 14.09; ESI-MS m/z calculated for C14H24O4S [M + H]+: 289.1; Found: 289.2 
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(2S,3R)-S-decyl 3-carbamoyloxirane-2-carbothioate (32). This compound was isolated as white 
solid (62%); 1H NMR (400 MHz, CDCl3) δ 6.32(bs, 1H), 5.57 (bs, 1H), 3.89 (d, J = 5.0, 1H), 3.72 (d, 
J = 5.0, 1H), 2.96 (m, 2H), 1.58 (dt, J = 15.0, 6.6, 2H), 1.27 (m, 14H), 0.88 (t, J = 6.8, 3H); 13C NMR 
(400 MHz, CDCl3) δ 192.58, 166.84, 58.91, 55.64, 31.85, 29.48, 29.41, 29.25, 29.15, 29.13, 29.00, 
28.72, 22.65, 14.09; ESI-MS m/z calculated for C1sH25NO3S [M + H]+: 288.16; Found: 288.2 
 
 
(Z)-methyl 3-(decylthio)acrylate(34). (E)-methyl 3-(decylthio)acrylate (35). Copper (I) chloride 
(59 mg, 0.6 mmol), potassium carbonate (165 mg, 1.19 mmol), DMSO (2 mL) were added to a 
Schlenk tube under argon atmosphere. Then Methylpropiolate (1 g, 11.89 mmol) and Decanethiol (2.2 
mL,10.70 mmol) were added using syringe. The tube was sealed with an oxygen balloon, then stirred 
at 70
o
C for 4h and monitored by TLC. Upon completion, the reaction mixture was cooled to room 
temperature and washed with 1 M hydrochloric acid (10 mL) solution, and the aqueous phase was re-
extracted with ethyl acetate (2x15 mL). The combined organic extracts were dried over Na
2
SO
4
, 
concentrated in vacuum, and the resulting residue was purified by silica gel column chromatography 
using 2% EA/HX. Both E, Z isomers were separated and obtained compounds 34 in 42% yield, 35 in 
20%; cis 1H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 10.2, 1H),  5.84 (d, J = 10.2, 1H), 3.74 (s, 3H),  
2.75 (t, J = 7.4, 2H), 1.67 (qu, J = 7.4, 2H), 1.39 (m, 2H), 1.28 (m, 12H), 0.88 (t, J = 6.8, 3H); 13C 
NMR (400 MHz, CDCl3) δ 167.05. 150.71, 112.47, 51.18, 36.06, 31.85, 30.30, 29.50, 29.44, 29.26, 
29.13, 28.43, 22.64, 14.08; ESI-MS m/z calculated for C14H26O2S [M + H]+: 259.2; Found: 259.2 
; trans 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 15.2, 1H),  5.74 (d, J = 15.2, 1H), 3.72 (s, 3H),  
2.78 (bt, 2H), 1.67 (qu, J = 7.3, 2H), 1.40 (qu, J = 6.2, 2H), 1.26 (m, 12H), 0.88 (t, J = 6.8, 3H); 13C 
NMR (400 MHz, CDCl3) δ 165.78, 147.28, 113.17, 51.38, 31.99, 31.85, 29.48, 29.42, 29.25, 29.06, 
28.75, 28.57, 22.65, 14.08; ESI-MS m/z calculated for C14H26O2S [M + H]+: 259.2; Found: 259.2 
 
 
(Z)-methyl 3-(decylsulfonyl)acrylate(36). To the stirred solution of sulfide (1.2 g, 4.64 mmol) in 
glacial acetic acid (10 ml), sodium perborate tetrahydrate (3.57 g, 23.21 mmol) was added in one 
portion and maintained at 50-60°C. Stirring was continued at 50-60°C for 3-4 h, until separation of 
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sodium borate was complete. The mixture was cooled, the inorganic salts removed by filtration with 
Ether (50 mL). The filtrate was concentrated under reduced pressure and purified by short column 
chromatography using 30% EA/HX. Obtained pure compound 36 in 50% yield; 1H NMR (400 MHz, 
CDCl3) δ 6.60 (d, J = 2.1, 1H), 3.85 (s, 3H),  3.22 (m, 2H), 1.83 (qu, J = 7.7, 2H), 1.43 (qu, J = 7.1, 
2H), 1.28 (m, 12H), 0.88 (t, J = 6.8, 3H); 13C NMR (400 MHz, CDCl3) δ 163.90, 136.42, 133.67 
55.50, 52.78, 31.82, 29.42, 29.21, 29.00, 28.38, 22.63, 21.94, 14.07; ESI-MS m/z calculated for 
C14H26O4S [M + H]+: 291.2; Found: 291.2 
 
 
(2S,3R)-methyl 3-(decylsulfonyl)oxirane-2-carboxylate (37). A 14.5% aqueous solution of sodium 
hypochlorite (1.6 mL, 3.78 mmol) was added dropwise at 0oC into a solution of sulfone 36 (500 mg, 
1.72 mmol) in 40 mL of a mixture of Ether/DMF (1:1). The mixture was stirred for 3 h at 0oC. Then 
the reaction was quenched by addition of 10% Na2S2O3 solution (30 mL). The aqueous phase was 
extracted with ether (3 x 15 mL).  The organic phase was dried over MgSO4 filtered, concentrated 
under reduced pressure. Crude was purified by Column chromatography using 30% EA/HX system. 
Obtained pure compound 37 in 70% yield; 1H NMR (400 MHz, CDCl3) δ 4.25 (d, J = 4.1, 1H), 3.87 
(d, J = 4.1, 1H), 3.85 (s, 3H),  3.16 (m, 2H), 1.88 (qu, J = 8.8, 2H), 1.45 (qu, J = 7.1, 2H), 1.28 (m, 
12H), 0.88 (t, J = 6.9, 3H); 13C NMR (400 MHz, CDCl3) δ 164.09, 66.02, 53.45, 53.09, 52.61, 31.80, 
29.40, 29.19, 29.18, 28.94, 28.37, 22.62, 21.11, 14.06; ESI-MS m/z calculated for C14H26O5S [M + 
H]+: 307.2; Found: 307.2 
 
 
(2S,3R)-3-(decylsulfonyl)oxirane-2-carboxylic acid (38). A stirred solution of Epoxy methyl ester 
37 (330 mg, 1.07 mmol) in tetrahydrofuran (8 mL) was prepared. A solution of lithium hydroxide 
monohydrate (91 mg, 2.15 mmol) in water (4 mL) was added. The reaction mixture was stirred at 
room temperature for 3 hours, then 2 M hydrochloric acid (5 mL) was added. The mixture was 
extracted ethyl acetate (2 x 20 mL), dried over anhydrous Na2SO4 filtered, concentrated under reduced 
pressure. Crude was purified by column chromatography using 30% ethylacetate/hexane. Obtained 
pure compound 38 in 68% yield; 1H NMR (400 MHz, CDCl3) δ 6.13 (bs, 1H), 4.31 (d, J = 4.2, 1H), 
3.92 (d, J = 4.2, 1H), 3.19 (m, 2H), 1.89 (qu, J = 8.4, 2H), 1.45 (qu, J = 7.1, 2H), 1.28 (m, 12H), 0.88 
(t, J = 6.8, 3H); 13C NMR (400 MHz, CDCl3) δ 166.17, 66.43, 53.33, 52.77, 31.82, 29.41, 29.21, 
29.20, 28.94, 28.37, 22.64, 21.17, 14.08; ESI-MS m/z calculated for C13H24O5S [M + H]+: 293.1; 
Found: 293.2 
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(2S,3R)-3-(decylsulfonyl)oxirane-2-carboxamide (39). This compound was isolated as white solid 
(60%); 1H NMR (400 MHz, CDCl3) δ 6.34 (bs, 1H), 5.81 (bs, 1H), 4.25 (d, J = 4.4, 1H), 3.80 (d, J = 
4.4, 1H), 3.12 (td, J = 7.4, 3.9 2H), 1.88 (qu, J = 7.9, 2H), 1.45 (qu, J = 7.0, 2H), 1.28 (m, 12H), 0.88 
(t, J = 6.8, 3H); 13C NMR (400 MHz, CDCl3) δ 165.32, 66.30, 54.28, 53.32, 31.82, 29.40, 29.20. 
29.19, 28.95, 28.40, 22.63, 21.26, 14.08; ESI-MS m/z calculated for C13H25NO4S [M + H]+: 292.2;  
Found: 292.2 
 
 
(Z)-4-(octyloxy)-4-oxobut-2-enoic acid (41). Maleic anhydride (98 mg, 1 mmol) and 1-octanol (0.19 
mL, 1.2 mmol) were dissolved in 5 mL Dichloromethane. After slowing adding triethylamine (0.21 
mL, 1.5mmol) to the mixture, the mixture was stirred at room temperature for 1 h. After reaction 
completion monitored by TLC, the reaction mixture was quenched with citric acid. The solution was 
diluted with 5mL Dichloromethane, washed with 1N HCl (2 x 3mL), dried over Na2SO4 and 
concentrated to dryness. The crude oil was purified via silica gel column chromatography (1:1 
EtOAc–Hexane) to yield the title compound (62 mg, 0.27 mmol, 27%) as colorless liquid; 1H NMR 
(400 MHz, CDCl3) δ 6.47 (d, J = 12.8, 1H),  6.37 (d, J = 12.8, 1H), 4.28 (t, J = 6.7, 2H), 1.75 (qu, J 
= 6.7, 2H), 1.32 (m, 10H), 0.87 (m, 3H) 
 
 
(Z)-octyl 4-amino-4-oxobut-2-enoate(42). Oxalyl chloride (76 ul, 0.88 mmol) was add to a stirred 
solution of ester acid 41 (101 mg, 0.44 mmol) in dichlorimethane (3 ml) under N2 atmosphere. 
Catalytic amount of DMF (2.3 ul, 0.03 mmol) was added and the mixture was stirred at room 
temperature for 1h. After reaction completion monitored by TLC, ammonium hydroxide (excess, 3.3 
ml) was added to reaction mixture and stirred for 5 hours. The reaction mixture was evaporated and 
diluted with EtOAc (10 ml), washed with brine (2 x 5 ml), dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo. The resulting residue was purified via silica gel column chromatography (1:1 
EtOAc–Hexane) to yield the title compound (35 mg, 0.15 mmol, 35%) as colorless liquid; H NMR 
(400 MHz, CDCl3) δ 6.92 (d, J = 15.5, 1H),  6.83 (d, J = 15.5, 1H), 5.60 (bd, 2H) 3.19 (t, J = 6.7, 
2H), 1.67 (m, 2H), 1.31 (m, 10H), 0.88 (bt, 3H) 
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